UA121017C2 - Композиція і спосіб моделювання експресії hbv - Google Patents

Композиція і спосіб моделювання експресії hbv Download PDF

Info

Publication number
UA121017C2
UA121017C2 UAA201511840A UAA201511840A UA121017C2 UA 121017 C2 UA121017 C2 UA 121017C2 UA A201511840 A UAA201511840 A UA A201511840A UA A201511840 A UAA201511840 A UA A201511840A UA 121017 C2 UA121017 C2 UA 121017C2
Authority
UA
Ukraine
Prior art keywords
nucleoside
group
oligonucleotide
antisense
hepmer
Prior art date
Application number
UAA201511840A
Other languages
English (en)
Ukrainian (uk)
Inventor
Тхазха П. Пракаш
Пуніт П. Сетх
Пунит П. Сетх
Ерік Е. Свайзе
Эрик Э. Свайзэ
Original Assignee
Айоніс Фармасьютікалз, Інк.
Айонис Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51843959&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA121017(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Айоніс Фармасьютікалз, Інк., Айонис Фармасьютикалз, Инк. filed Critical Айоніс Фармасьютікалз, Інк.
Publication of UA121017C2 publication Critical patent/UA121017C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Liquid Crystal Substances (AREA)
UAA201511840A 2013-05-01 2014-05-01 Композиція і спосіб моделювання експресії hbv UA121017C2 (uk)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361818442P 2013-05-01 2013-05-01
US201361823826P 2013-05-15 2013-05-15
US201361843887P 2013-07-08 2013-07-08
US201361871673P 2013-08-29 2013-08-29
US201361880790P 2013-09-20 2013-09-20
US201461976991P 2014-04-08 2014-04-08
US201461986867P 2014-04-30 2014-04-30
PCT/US2014/036463 WO2014179627A2 (en) 2013-05-01 2014-05-01 Compositions and methods for modulating hbv and ttr expression

Publications (1)

Publication Number Publication Date
UA121017C2 true UA121017C2 (uk) 2020-03-25

Family

ID=51843959

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201511840A UA121017C2 (uk) 2013-05-01 2014-05-01 Композиція і спосіб моделювання експресії hbv
UAA201708429A UA120287C2 (uk) 2013-05-01 2014-05-01 Сполука, яка здатна інгібувати експресію ттr, та її застосування

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201708429A UA120287C2 (uk) 2013-05-01 2014-05-01 Сполука, яка здатна інгібувати експресію ттr, та її застосування

Country Status (40)

Country Link
US (27) US9714421B2 (enExample)
EP (13) EP3828275A1 (enExample)
JP (23) JP6456362B2 (enExample)
KR (17) KR102712053B1 (enExample)
CN (13) CN105378082B (enExample)
AU (20) AU2014259756B2 (enExample)
BR (6) BR122018009831B1 (enExample)
CA (5) CA2921167C (enExample)
CL (2) CL2015003217A1 (enExample)
CR (2) CR20190269A (enExample)
CY (2) CY1121879T1 (enExample)
DK (4) DK2992098T3 (enExample)
DO (3) DOP2015000268A (enExample)
EA (2) EA036584B1 (enExample)
ES (4) ES2778442T3 (enExample)
FI (1) FIC20250028I1 (enExample)
FR (1) FR25C1033I1 (enExample)
HR (2) HRP20201378T1 (enExample)
HU (2) HUE050394T2 (enExample)
IL (19) IL284593B2 (enExample)
LT (2) LT2992098T (enExample)
MA (1) MA60161B1 (enExample)
ME (1) ME03390B (enExample)
MX (12) MX373306B (enExample)
MY (2) MY178929A (enExample)
NL (1) NL301341I2 (enExample)
NO (1) NO2025037I1 (enExample)
NZ (5) NZ631552A (enExample)
PE (2) PE20161430A1 (enExample)
PH (3) PH12015502493B1 (enExample)
PL (2) PL2992009T3 (enExample)
PT (3) PT2992098T (enExample)
RS (2) RS58981B1 (enExample)
RU (8) RU2650510C2 (enExample)
SG (5) SG11201508800WA (enExample)
SI (2) SI2992009T1 (enExample)
SM (1) SMT201900316T1 (enExample)
UA (2) UA121017C2 (enExample)
WO (5) WO2014179629A2 (enExample)
ZA (2) ZA201507216B (enExample)

Families Citing this family (504)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101979134B1 (ko) 2008-10-15 2019-05-15 아이오니스 파마수티컬즈, 인코포레이티드 인자 １１ 발현의 조정
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
CA2817960C (en) 2010-11-17 2020-06-09 Isis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
BR112014001244A2 (pt) 2011-07-19 2017-02-21 Wave Life Sciences Pte Ltd métodos para a síntese de ácidos nucléicos funcionalizados
US10023861B2 (en) 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
WO2013148260A1 (en) 2012-03-30 2013-10-03 Washington University Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
WO2013159108A2 (en) * 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
RU2624028C2 (ru) * 2012-05-24 2017-06-30 Ионис Фармасьютикалз, Инк. Способы и композиции для модулирования экспрессии аполипопротеина (а)
MX356830B (es) 2012-07-13 2018-06-15 Shin Nippon Biomedical Laboratories Ltd Adyuvante de acido nucleico quiral.
SG10201912895PA (en) 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
CN104684893B (zh) 2012-07-13 2016-10-26 日本波涛生命科学公司 不对称辅助基团
EP3406718A1 (en) 2012-11-15 2018-11-28 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
RU2649367C2 (ru) * 2013-01-30 2018-04-02 Ф. Хоффманн-Ля Рош Аг Конъюгаты углевода и lna-олигонуклеотида
ES2961686T3 (es) * 2013-02-14 2024-03-13 Ionis Pharmaceuticals Inc Modulación de la expresión de apolipoproteína C-III (APOCIII) en poblaciones deficientes en lipoproteína lipasa (LPLD)
US9506030B2 (en) 2013-05-01 2016-11-29 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
CN105378082B (zh) 2013-05-01 2020-06-09 Ionis制药公司 组合物和方法
TW201446791A (zh) 2013-05-01 2014-12-16 Regulus Therapeutics Inc 用於調節mir-122之微小rna化合物及方法
WO2014207232A1 (en) 2013-06-27 2014-12-31 Santaris Pharma A/S Antisense oligomers and conjugates targeting pcsk9
EP3019200B1 (en) * 2013-07-11 2022-03-23 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
EP3022176B8 (en) 2013-07-15 2019-12-25 The Regents of the University of California Azacyclic constrained analogs of fty720
TW202246503A (zh) 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
US9943604B2 (en) 2013-09-20 2018-04-17 Ionis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
CA2925107A1 (en) * 2013-10-02 2015-04-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
EP3060664B1 (en) 2013-10-25 2021-07-07 Sanofi Microrna compounds and methods for modulating mir-21 activity
RU2016122168A (ru) * 2013-11-14 2017-12-19 Рош Инновейшен Сентер Копенгаген А/С Антисмысловые конъюгаты, направленные на аполипопротеин b
JP6482475B2 (ja) * 2014-01-07 2019-03-13 レナセラピューティクス株式会社 アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
RU2016133035A (ru) 2014-01-16 2018-02-21 Уэйв Лайф Сайенсес Лтд. Хиральный дизайн
CN106103718B (zh) 2014-02-11 2021-04-02 阿尔尼拉姆医药品有限公司 己酮糖激酶(KHK)iRNA组合物及其使用方法
WO2015143246A1 (en) 2014-03-19 2015-09-24 Isis Pharmaceuticals, Inc. Compositions for modulating ataxin 2 expression
US10006027B2 (en) 2014-03-19 2018-06-26 Ionis Pharmaceuticals, Inc. Methods for modulating Ataxin 2 expression
PL3757214T3 (pl) 2014-04-01 2022-09-12 Biogen Ma Inc. Kompozycje do modulowania ekspresji sod-1
PL3137605T3 (pl) 2014-05-01 2021-04-19 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji białka angiopoetynopodobnego 3
ES2812099T3 (es) 2014-05-01 2021-03-16 Ionis Pharmaceuticals Inc Composiciones y métodos para modular la expresión del receptor de la hormona del crecimiento
CA2943894A1 (en) 2014-05-01 2015-11-05 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating complement factor b expression
MX377141B (es) 2014-05-01 2025-03-07 Ionis Pharmaceuticals Inc Composiciones y metodos para modular la expresion de pkk.
EP3811977B1 (en) * 2014-05-01 2025-12-03 Ionis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
GB201408623D0 (en) * 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
BR112016026950B1 (pt) 2014-05-22 2023-03-07 Alnylam Pharmaceuticals, Inc Agente de ácido ribonucleico (rnai) de fita dupla, seus usos e composição farmacêutica
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
BR112017001931A2 (pt) 2014-08-07 2017-11-28 Regulus Therapeutics Inc direcionamento de micrornas para distúrbios metabólicos
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
JP6867945B2 (ja) 2014-10-03 2021-05-12 コールド スプリング ハーバー ラボラトリー 核内遺伝子出力の標的とされた増強
SG11201702877TA (en) 2014-10-10 2017-05-30 Hoffmann La Roche Galnac phosphoramidites, nucleic acid conjugates thereof and their use
WO2016061487A1 (en) * 2014-10-17 2016-04-21 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
EP3221451A1 (en) 2014-11-17 2017-09-27 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
JP2018504380A (ja) 2014-12-18 2018-02-15 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｒｅｖｅｒｓｉｒ（商標）化合物
US10793855B2 (en) 2015-01-06 2020-10-06 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
WO2016115490A1 (en) 2015-01-16 2016-07-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of dux4
AU2016219263B2 (en) 2015-02-13 2022-12-01 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
CN107466323A (zh) 2015-02-15 2017-12-12 阿克丘勒斯治疗公司 酰基‑氨基‑lna和/或烃基‑氨基‑lna寡核苷酸
US11129844B2 (en) 2015-03-03 2021-09-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating MECP2 expression
JP6892433B2 (ja) 2015-04-03 2021-06-23 ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ 十分に安定化された非対称ｓｉｒｎａ
HK1249140A1 (zh) * 2015-04-03 2018-10-26 Ionis Pharmaceuticals, Inc. 用於调节tmprss6表达的化合物和方法
MX2017012610A (es) 2015-04-08 2018-03-16 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen lect2.
US10407678B2 (en) 2015-04-16 2019-09-10 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
EP3286310A4 (en) 2015-04-24 2019-01-09 California Institute of Technology REACTIVATION OF X-CHROMOSOME GENES
EP3310918B1 (en) 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en) 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
CA2990699A1 (en) 2015-06-29 2017-01-05 Ionis Pharmaceuticals, Inc. Modified crispr rna and modified single crispr rna and uses thereof
WO2017011276A1 (en) 2015-07-10 2017-01-19 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (dgat2)
US10494632B2 (en) 2015-07-10 2019-12-03 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
JPWO2017010575A1 (ja) * 2015-07-16 2018-04-26 協和発酵キリン株式会社 β２ＧＰＩ遺伝子発現抑制核酸複合体
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
CA2982825C (en) 2015-08-06 2023-10-17 F. Hoffmann-La Roche Ag Processes for the preparation of galnac acid derivatives
CA2995110A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
CN105111119B (zh) * 2015-08-14 2017-04-12 天津小新医药科技有限公司 一类卤代苯l‑薄荷醇类p2y12受体拮抗剂及其用途
CN105111118B (zh) * 2015-08-14 2017-04-12 天津小新医药科技有限公司 L‑薄荷醇类p2y12受体拮抗剂、制备方法及其用途
KR20180043819A (ko) 2015-08-24 2018-04-30 로슈 이노베이션 센터 코펜하겐 에이/에스 Lna-g 방법
EP3344769B1 (en) 2015-09-02 2024-04-17 Alnylam Pharmaceuticals, Inc. Programmed cell death 1 ligand 1 (pd-l1) irna compositions and methods of use thereof
RU2018113709A (ru) 2015-09-24 2019-10-30 Айонис Фармасьютикалз, Инк. Модуляторы экспрессии kras
CN108366990B (zh) 2015-09-24 2021-09-03 加利福尼亚大学董事会 合成的鞘脂类分子、药物、它们的合成方法及治疗方法
US20180273948A1 (en) * 2015-09-25 2018-09-27 Tarveda Therapeutics, Inc. RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF
EP3353303B1 (en) 2015-09-25 2023-08-02 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating ataxin 3 expression
EP3353305A4 (en) * 2015-09-25 2019-09-18 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
WO2017053999A1 (en) 2015-09-25 2017-03-30 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
JOP20210043A1 (ar) * 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
CN108136041B (zh) 2015-10-02 2022-12-30 罗氏创新中心哥本哈根有限公司 寡核苷酸缀合方法
KR20240033305A (ko) 2015-10-08 2024-03-12 아이오니스 파마수티컬즈, 인코포레이티드 앤지오텐시노겐 발현 조정을 위한 화합물 및 방법
WO2017060731A1 (en) 2015-10-09 2017-04-13 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
WO2017068087A1 (en) 2015-10-22 2017-04-27 Roche Innovation Center Copenhagen A/S Oligonucleotide detection method
WO2017067970A1 (en) 2015-10-22 2017-04-27 Roche Innovation Center Copenhagen A/S In vitro toxicity screening assay
CN113952353A (zh) * 2015-11-06 2022-01-21 Ionis制药公司 调节载脂蛋白(a)表达
PL4119569T3 (pl) 2015-11-06 2024-11-18 Ionis Pharmaceuticals, Inc. Sprzężone związki antysensowne do zastosowania w terapii
KR102117172B1 (ko) * 2015-11-16 2020-06-01 에프. 호프만-라 로슈 아게 GalNAc 클러스터 포스포라미다이트
WO2017096395A1 (en) 2015-12-04 2017-06-08 Ionis Pharmaceuticals, Inc. Methods of treating breast cancer
AU2016370653A1 (en) 2015-12-14 2018-06-21 Cold Spring Harbor Laboratory Antisense oligomers for treatment of Autosomal Dominant Mental Retardation-5 and Dravet Syndrome
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
AU2016381174A1 (en) 2015-12-31 2018-05-31 Ionis Pharmaceuticals, Inc. Methods for reducing Ataxin-2 expression
EP3400300A4 (en) 2016-01-05 2019-08-07 Ionis Pharmaceuticals, Inc. PROCESS FOR REDUCING LRRK2 EXPRESSION
EP3402900A1 (en) 2016-01-12 2018-11-21 Interleukin Genetics, Inc. Methods for predicting response to treatment
US11530409B2 (en) 2016-01-26 2022-12-20 Nissan Chemical Corporation Single-stranded oligonucleotide
ES2858090T3 (es) * 2016-01-29 2021-09-29 Kyowa Kirin Co Ltd Complejo de ácidos nucleicos
AU2017210726B2 (en) * 2016-01-31 2023-08-03 University Of Massachusetts Branched oligonucleotides
KR102348425B1 (ko) 2016-03-07 2022-01-10 애로우헤드 파마슈티컬스 인코포레이티드 치료용 화합물을 위한 표적화 리간드
WO2017156242A1 (en) 2016-03-09 2017-09-14 Ionis Pharmaceuticals, Inc. Methods and compositions for inhibiting pmp22 expression
RU2747822C2 (ru) 2016-03-14 2021-05-14 Ф. Хоффманн-Ля Рош Аг Олигонуклеотиды для понижения экспрессии pd-l1
WO2017161168A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Modulation of dyrk1b expression
CA3013799A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Methods of modulating keap1
EP3228326A1 (en) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Nucleic acid linked to a trivalent glycoconjugate
MA45478A (fr) * 2016-04-11 2019-02-20 Arbutus Biopharma Corp Compositions de conjugués d'acides nucléiques ciblés
EP3443094B1 (en) 2016-04-13 2022-10-19 Ionis Pharmaceuticals, Inc. Methods for reducing c9orf72 expression
WO2017178656A1 (en) 2016-04-14 2017-10-19 Roche Innovation Center Copenhagen A/S TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
MA45295A (fr) 2016-04-19 2019-02-27 Alnylam Pharmaceuticals Inc Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
WO2017188898A1 (en) 2016-04-29 2017-11-02 Nanyang Technological University G-quadruplex-containing antisense oligonucleotides
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
EP3452049A4 (en) 2016-05-06 2020-01-08 Ionis Pharmaceuticals, Inc. GLP-1 RECEPTOR LIGAND PART CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
US11479818B2 (en) 2016-06-17 2022-10-25 Hoffmann-La Roche Inc. In vitro nephrotoxicity screening assay
AU2017286811A1 (en) 2016-06-17 2018-11-22 Ionis Pharmaceuticals, Inc. Modulation of gys1 expression
EP3472348B1 (en) 2016-06-17 2022-06-29 F. Hoffmann-La Roche AG In vitro nephrotoxicity screening assay
AU2017281497B2 (en) 2016-06-22 2023-04-06 Proqr Therapeutics Ii B.V. Single-stranded RNA-editing oligonucleotides
CA3029508A1 (en) 2016-06-30 2018-01-04 Kyowa Hakko Kirin Co., Ltd. Nucleic acid conjugate
EP3481430A4 (en) 2016-07-11 2020-04-01 Translate Bio Ma, Inc. NUCLEIC ACID CONJUGATES AND USES THEREOF
IL308256A (en) 2016-07-15 2024-01-01 Ionis Pharmaceuticals Inc Compounds and methods for modulation of smn2
IL291323B2 (en) 2016-07-15 2023-09-01 Am Chemicals Llc Solid non-nucleoside supports and phosphoramidite building blocks for oligonucleotide synthesis
WO2018031933A2 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
US11981703B2 (en) 2016-08-17 2024-05-14 Sirius Therapeutics, Inc. Polynucleotide constructs
JP7244922B2 (ja) 2016-09-01 2023-03-23 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 化学修飾された一本鎖ｒｎａ編集オリゴヌクレオチド
US10294474B2 (en) 2016-09-02 2019-05-21 Arrowhead Pharmaceuticals, Inc. Targeting ligands
WO2018057837A1 (en) * 2016-09-23 2018-03-29 Ionis Pharmaceuticals, Inc. Gene therapy and targeted delivery of conjugated compounds
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
CN109661233A (zh) * 2016-10-06 2019-04-19 Ionis 制药公司 缀合低聚化合物的方法
EP3532044A4 (en) 2016-10-27 2020-07-29 California Institute of Technology HDAC INHIBITOR COMPOSITIONS FOR CHROMOSOME X REACTIVATION
JOP20190104A1 (ar) 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن atxn3
EP3538654A1 (en) * 2016-11-11 2019-09-18 Janssen BioPharma, Inc. Oligonucleotide targeting strategy for hbv cccdna
TWI788312B (zh) 2016-11-23 2023-01-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
WO2018102745A1 (en) 2016-12-02 2018-06-07 Cold Spring Harbor Laboratory Modulation of lnc05 expression
JP6811338B2 (ja) * 2016-12-13 2021-01-13 エーエム サイエンシーズ インコーポレイテッド Ｂ型肝炎の予防または治療用医薬組成物
SG10201913552UA (en) 2016-12-16 2020-03-30 Alnylam Pharmaceuticals Inc Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
CN108239644B (zh) * 2016-12-23 2021-05-28 苏州瑞博生物技术股份有限公司 一种小干扰核酸和药物组合物及其用途
US10337070B2 (en) 2017-01-12 2019-07-02 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
WO2018130585A1 (en) 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating relb expression
US20190345495A1 (en) 2017-01-13 2019-11-14 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb2 expression
EP3568478A1 (en) 2017-01-13 2019-11-20 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating rel expression
US20190367920A1 (en) 2017-01-13 2019-12-05 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb1 expression
US20200216845A1 (en) 2017-01-13 2020-07-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating rela expression
TWI830693B (zh) 2017-02-06 2024-02-01 日商日產化學工業股份有限公司 單股寡核苷酸
US11180756B2 (en) * 2017-03-09 2021-11-23 Ionis Pharmaceuticals Morpholino modified oligomeric compounds
US11963974B2 (en) 2017-03-10 2024-04-23 National Center For Child Health And Development Antisense oligonucleotide and composition for prevention or treatment of glycogen storage disease type Ia
JOP20190215A1 (ar) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9
EP3385272A1 (en) * 2017-04-05 2018-10-10 Silence Therapeutics GmbH Further novel oligonucleotide-ligand conjugates
EP3607069B1 (en) 2017-04-05 2022-11-02 Silence Therapeutics GmbH Products and compositions
BR112019021359A2 (pt) 2017-04-11 2020-05-05 Arbutus Biopharma Corporation moléculas, composições, compostos, métodos para administrar um sirna, para preparar um composto e para tratar uma infecção, composto ou sal, conjugado de galnac e uso de um composto
IL269927B2 (en) 2017-04-18 2025-04-01 Alnylam Pharmaceuticals Inc Methods of treating patients with hepatitis B virus infection
WO2018215049A1 (en) 2017-05-23 2018-11-29 F. Hoffmann-La Roche Ag Process for galnac oligonucleotide conjugates
WO2018216785A1 (ja) * 2017-05-26 2018-11-29 国立研究開発法人国立循環器病研究センター Ｐｃｓｋ９を標的としたアンチセンス核酸
CN111050806A (zh) * 2017-06-02 2020-04-21 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
EP3630788A4 (en) * 2017-06-02 2021-04-28 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THEIR USE
WO2018226788A1 (en) 2017-06-07 2018-12-13 University Of Massachusetts Anti-adam33 oligonucleotides and related methods
JP7406793B2 (ja) 2017-06-23 2023-12-28 ユニバーシティー オブ マサチューセッツ ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
EP3652317A1 (en) 2017-07-13 2020-05-20 Alnylam Pharmaceuticals, Inc. Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
AU2018307294B2 (en) 2017-07-26 2025-04-17 Nissan Chemical Corporation Single-stranded oligonucleotide
WO2019027009A1 (ja) * 2017-08-02 2019-02-07 協和発酵キリン株式会社 核酸複合体
TW201909925A (zh) * 2017-08-02 2019-03-16 日商協和醱酵麒麟有限公司 核酸複合體
WO2019030313A2 (en) 2017-08-11 2019-02-14 Roche Innovation Center Copenhagen A/S OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
WO2019036612A1 (en) 2017-08-17 2019-02-21 Alnylam Pharmaceuticals, Inc. ADJUSTABLE REVERSIR TM COMPOUNDS
AU2018318231A1 (en) 2017-08-18 2020-02-13 Ionis Pharmaceuticals, Inc. Modulation of the notch signaling pathway for treatment of respiratory disorders
WO2019038228A1 (en) 2017-08-22 2019-02-28 Roche Innovation Center Copenhagen A/S OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
LT3673080T (lt) 2017-08-25 2023-12-27 Stoke Therapeutics, Inc. Priešprasminiai oligomerai, skirti būklėms ir ligoms gydyti
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
WO2019053661A2 (en) * 2017-09-14 2019-03-21 Alios Biopharma, Inc. GALNAC DERIVATIVES
CA3071712C (en) 2017-09-29 2023-02-14 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus and methods of use
AU2018338787C1 (en) 2017-09-29 2025-10-23 Intellia Therapeutics, Inc. Compositions and methods for TTR gene editing and treating ATTR amyloidosis
WO2019073018A1 (en) 2017-10-13 2019-04-18 Roche Innovation Center Copenhagen A/S METHODS OF IDENTIFYING ANTISENSE OLIGONUCLEOTIDE IMPROVED OLIGONUCLEOTIDE PHOSPHOROTHIOATE STEREODEFINIS VARIANTS USING PARTIALLY STEREODEFINIS OLIGONUCLEOTIDE SUB LIBRARIES
RU2766360C2 (ru) 2017-10-16 2022-03-15 Ф. Хоффманн-Ля Рош Аг МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В
US11866701B2 (en) 2017-11-01 2024-01-09 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
TWI809004B (zh) 2017-11-09 2023-07-21 美商Ionis製藥公司 用於降低snca表現之化合物及方法
EP3710587A1 (en) 2017-11-16 2020-09-23 Alnylam Pharmaceuticals, Inc. Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019100039A1 (en) 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
CN118291457A (zh) 2017-12-01 2024-07-05 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019105404A1 (zh) * 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019105419A1 (zh) * 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019105403A1 (zh) * 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019105435A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
HRP20250277T1 (hr) 2017-12-01 2025-05-09 Suzhou Ribo Life Science Co., Ltd. Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba
US12083142B2 (en) * 2017-12-01 2024-09-10 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US20200385714A1 (en) 2017-12-11 2020-12-10 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating fndc3b expression
WO2019115417A2 (en) 2017-12-12 2019-06-20 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating rb1 expression
US11725208B2 (en) 2017-12-14 2023-08-15 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
BR112020012088A2 (pt) 2017-12-18 2020-11-17 Alnylam Pharmaceuticals, Inc. composições de irna do grupo de elevada mobilidade box-1 (hmgb1) e métodos de uso dos mesmos
WO2019126641A2 (en) 2017-12-21 2019-06-27 Ionis Pharmaceuticals, Inc. Modulation of frataxin expression
MX2020005872A (es) 2017-12-21 2020-08-13 Hoffmann La Roche Diagnostico complementario para antagonistas de acido ribonucleico (arn) de proteina a1 de alto requerimiento de temperatura a (htra1).
US20200332289A1 (en) 2017-12-22 2020-10-22 Roche Innovation Center Copenhagen A/S Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
TW201929870A (zh) 2017-12-22 2019-08-01 丹麥商羅氏創新中心哥本哈根有限公司 包含二硫代磷酸酯核苷間連結之寡核苷酸
WO2019122277A1 (en) 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Novel thiophosphoramidites
US11485752B2 (en) * 2017-12-26 2022-11-01 Guangzhou Ribobio Co., Ltd. Modified oligonucleotides and compound that can be used for synthesizing same
CN109957566B (zh) * 2017-12-26 2023-08-25 广州市锐博生物科技有限公司 修饰的寡核苷酸和可用于合成修饰的寡核苷酸的化合物
CA3087106A1 (en) 2017-12-29 2019-07-04 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
WO2019140102A1 (en) 2018-01-10 2019-07-18 Translate Bio Ma, Inc. Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
CN111699258A (zh) 2018-01-10 2020-09-22 哥本哈根罗氏创新中心 用于调控pias4表达的寡核苷酸
US20210095275A1 (en) 2018-01-12 2021-04-01 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating gsk3b expression
BR112020014011A2 (pt) 2018-01-12 2020-12-08 Bristol-Myers Squibb Company Oligonucleotídeos antissenso dirigidos à alfa-sinucleína e usos dos mesmos
IL275902B2 (en) 2018-01-12 2025-10-01 Bristol Myers Squibb Co Antisense oligonucleotides directed against alpha-synuclein and their uses
BR112020012921A2 (pt) 2018-01-12 2020-12-08 Roche Innovation Center Copenhagen A/S Oligonucleotídeos antissenso de alfa-sinucleína e usos dos mesmos
WO2019140452A1 (en) 2018-01-15 2019-07-18 Ionis Pharmaceuticals, Inc. Modulators of dnm2 expression
JP2021510525A (ja) 2018-01-17 2021-04-30 ロシュ イノベーション センター コペンハーゲン エーエス Ｅｒｃ１発現を調節するためのオリゴヌクレオチド
US20210095277A1 (en) 2018-01-18 2021-04-01 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting srebp1
WO2019145386A1 (en) 2018-01-26 2019-08-01 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating csnk1d expression
WO2019157531A1 (en) 2018-02-12 2019-08-15 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
JP2021513851A (ja) 2018-02-14 2021-06-03 ディープ ゲノミクス インコーポレイテッドＤｅｅｐ Ｇｅｎｏｍｉｃｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ウィルソン病に対するオリゴヌクレオチド療法
IL320427A (en) 2018-02-21 2025-06-01 Bristol Myers Squibb Co CAMK2D antisense oligonucleotides and their uses
EP3759127A4 (en) 2018-03-02 2022-03-30 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN
TWI840345B (zh) 2018-03-02 2024-05-01 美商Ionis製藥公司 Irf4表現之調節劑
CN111511915A (zh) * 2018-03-09 2020-08-07 第一三共株式会社 糖原病Ia型治疗药
EP3768694A4 (en) 2018-03-22 2021-12-29 Ionis Pharmaceuticals, Inc. Methods for modulating fmr1 expression
AU2019247645A1 (en) 2018-04-05 2020-10-15 Centre Leon Berard Use of FUBP1 inhibitors for treating hepatitis B virus infection
BR112020018698A2 (pt) 2018-04-11 2021-01-05 Ionis Pharmaceuticals, Inc. Moduladores de expressão de ezh2
US12263205B2 (en) 2018-04-30 2025-04-01 The Children's Hospital Of Philadelphia Methods of improving anemias by combining agents
CA3099280A1 (en) 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
US20210269851A1 (en) 2018-05-07 2021-09-02 Roche Innovation Center Copenhagen A/S Massively parallel discovery methods for oligonucleotide therapeutics
TWI854980B (zh) 2018-05-08 2024-09-11 美商雷格勒斯治療公司 用於調節mir-122之微小rna化合物及方法
EP4663758A2 (en) 2018-05-09 2025-12-17 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing atxn3 expression
MY204000A (en) * 2018-05-09 2024-07-31 Ionis Pharmaceuticals Inc Compounds and methods for reducing fxi expression
US12391942B2 (en) 2018-05-11 2025-08-19 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
TWI851574B (zh) 2018-05-14 2024-08-11 美商阿尼拉製藥公司 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
AU2019287635A1 (en) 2018-06-14 2020-12-17 Ionis Pharmaceuticals, Inc. Compounds and methods for increasing STMN2 expression
TWI833770B (zh) 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法
EP3818159A1 (en) 2018-07-03 2021-05-12 F. Hoffmann-La Roche AG Oligonucleotides for modulating tau expression
WO2020007826A1 (en) 2018-07-05 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting mbtps1
WO2020011744A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting cers5
WO2020011745A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting cers6
EP4512407A3 (en) 2018-07-13 2025-09-24 F. Hoffmann-La Roche AG Oligonucleotides for modulating rtel1 expression
WO2020023737A1 (en) 2018-07-25 2020-01-30 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing atxn2 expression
TW202020155A (zh) 2018-07-31 2020-06-01 丹麥商羅氏創新中心哥本哈根有限公司 含有三硫代磷酸酯核苷間連結之寡核苷酸
MX2020013270A (es) 2018-07-31 2021-02-18 Roche Innovation Ct Copenhagen As Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato.
EP3833397A4 (en) 2018-08-08 2023-06-14 Arcturus Therapeutics, Inc. COMPOSITIONS AND AGENTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS
AU2019316640A1 (en) 2018-08-10 2021-03-18 University Of Massachusetts Modified oligonucleotides targeting SNPs
TW202023574A (zh) 2018-08-13 2020-07-01 美商阿尼拉製藥公司 Ｂ型肝炎病毒（ＨＢＶ）ｄｓＲＮＡ劑組合物及其使用方法
WO2020038377A1 (zh) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
US11279930B2 (en) 2018-08-23 2022-03-22 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
EP3844274A1 (en) 2018-08-28 2021-07-07 Roche Innovation Center Copenhagen A/S Neoantigen engineering using splice modulating compounds
WO2020060986A1 (en) 2018-09-18 2020-03-26 Alnylam Pharmaceuticals, Inc. Ketohexokinase (khk) irna compositions and methods of use thereof
TWI856973B (zh) 2018-09-19 2024-10-01 美商Ionis製藥公司 Pnpla3表現之調節劑
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
WO2020077390A1 (en) * 2018-10-18 2020-04-23 Murdoch University Antisense therapy for ptp1b related conditions
US10913951B2 (en) 2018-10-31 2021-02-09 University of Pittsburgh—of the Commonwealth System of Higher Education Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
CN113286885A (zh) 2018-11-09 2021-08-20 诺华股份有限公司 用靶向apo(a)的经缀合的反义化合物降低心血管事件的风险的方法
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
BR112021008967A2 (pt) 2018-11-15 2021-08-17 Ionis Pharmaceuticals, Inc. moduladores da expressão de irf5
SG11202103794QA (en) 2018-11-21 2021-05-28 Ionis Pharmaceuticals Inc Compounds and methods for reducing prion expression
JP7707065B2 (ja) 2018-11-23 2025-07-14 サノフイ Ａｎｇｐｔｌ８を阻害するための新規のｒｎａ組成物および方法
US20220127605A1 (en) 2018-11-30 2022-04-28 Kyowa Kirin Co., Ltd. Nucleic acid conjugate
US12485136B2 (en) 2018-12-03 2025-12-02 Takeda Pharmaceuticals U.S.A., Inc. Methods for the treatment of trinucleotide repeat expansion disorders associated with MLH3 activity
EP3898977A1 (en) 2018-12-20 2021-10-27 Praxis Precision Medicines, Inc. Compositions and methods for the treatment of kcnt1 related disorders
EP3899024A4 (en) 2018-12-21 2023-05-31 Ionis Pharmaceuticals, Inc. Modulators of hsd17b13 expression
CN112423794A (zh) * 2018-12-28 2021-02-26 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
CN111377985B (zh) * 2018-12-29 2023-11-10 苏州瑞博生物技术股份有限公司 化合物和缀合物及其制备方法和用途
US11492619B2 (en) 2019-01-18 2022-11-08 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
CN113330117B (zh) * 2019-01-18 2024-05-28 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
BR112021013369A2 (pt) 2019-01-31 2021-09-21 Ionis Pharmaceuticals, Inc. Moduladores de expressão de yap1
CA3129646A1 (en) 2019-02-20 2020-08-27 Roche Innovation Center Copenhagen A/S Novel phosphoramidites
JP2022521510A (ja) 2019-02-20 2022-04-08 ロシュ イノベーション センター コペンハーゲン エーエス ホスホノアセテートギャップマー型オリゴヌクレオチド
CN109799330B (zh) * 2019-02-22 2021-03-02 华中科技大学同济医学院附属同济医院 神经氨酸及神经氨酸酶抑制剂在慢性心力衰竭中的应用
CN113474633A (zh) 2019-02-26 2021-10-01 罗氏创新中心哥本哈根有限公司 寡核苷酸配制方法
SG11202108450SA (en) 2019-02-27 2021-09-29 Ionis Pharmaceuticals Inc Modulators of malat1 expression
CA3128577A1 (en) * 2019-02-28 2020-09-03 Jovanka BOGOJESKI Ligand clusters and methods of their use and preparation
JP2022527569A (ja) * 2019-03-21 2022-06-02 ミトセラピューティクス・エルエルシー 治療剤の標的化送達のための多価リガンドクラスター
LT3947684T (lt) 2019-03-29 2025-05-26 Ionis Pharmaceuticals, Inc. Ube3a-ats moduliavimui skirti junginiai ir būdai
WO2020201144A1 (en) 2019-04-02 2020-10-08 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for immunotherapy
BR112021019182A2 (pt) 2019-04-03 2022-05-31 Bristol Myers Squibb Co Oligonucleotídeos angptl2 antissenso e seus usos
US20220251128A1 (en) * 2019-05-17 2022-08-11 Ionis Pharmaceuticals, Inc. Synthesis of oligomeric compounds comprising phosphorothioate diester and phosphodiester linkages
TWI863999B (zh) 2019-05-22 2024-12-01 大陸商蘇州瑞博生物技術股份有限公司 ｓｉＲＮＡ綴合物、其用途及使用其之方法
JP7610848B2 (ja) 2019-05-22 2025-01-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体ならびに調製方法と使用
AU2020280438B2 (en) 2019-05-22 2025-03-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
CA3141372A1 (en) 2019-05-22 2020-11-26 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
KR20220012284A (ko) 2019-05-24 2022-02-03 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 약학 조성물, 컨쥬게이트와 이의 제조 방법 및 용도
EP3992290A4 (en) 2019-05-24 2023-11-15 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
JP7610849B2 (ja) 2019-05-24 2025-01-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体ならびに調製方法と使用
EP4556565A2 (en) 2019-05-28 2025-05-21 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing fus expression
PE20220574A1 (es) 2019-05-31 2022-04-20 Aligos Therapeutics Inc Oligonucleotidos gapmer modificados y metodos de uso
JP7610339B2 (ja) 2019-06-04 2025-01-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法
US20220363711A1 (en) 2019-06-25 2022-11-17 Amgen Inc. Purification methods for carbohydrate-linked oligonucleotides
EP3956450B1 (en) 2019-07-26 2025-08-13 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating gfap
WO2021022109A1 (en) 2019-08-01 2021-02-04 Alnylam Pharmaceuticals, Inc. SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4007811A2 (en) 2019-08-01 2022-06-08 Alnylam Pharmaceuticals, Inc. Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof
BR112022002307A2 (pt) 2019-08-09 2022-06-28 Univ Massachusetts Oligonucleotídeos quimicamente modificados que têm como alvo snps
EP4013870A1 (en) 2019-08-13 2022-06-22 Alnylam Pharmaceuticals, Inc. Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof
KR20220062517A (ko) * 2019-08-15 2022-05-17 아이오니스 파마수티컬즈, 인코포레이티드 결합 변형된 올리고머 화합물 및 이의 용도
CN115176011B (zh) 2019-08-27 2025-11-11 赛诺菲 用于抑制pcsk9的组合物和方法
EP4023659A4 (en) 2019-08-29 2024-02-28 Suzhou Ribo Life Science Co., Ltd. COMPOUND AND DRUG CONJUGATE, PRODUCTION METHOD AND USE THEREOF
EP4022062A1 (en) 2019-08-30 2022-07-06 Alnylam Pharmaceuticals, Inc. Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy
EP4025252A4 (en) * 2019-09-03 2023-10-18 Arcturus Therapeutics, Inc. ASIALOGLYCOPROTEIN RECEPTOR-MEDIATED ADMINISTRATION OF THERAPEUTICALLY ACTIVE CONJUGATES
BR112022004461A2 (pt) * 2019-09-10 2022-07-19 Daiichi Sankyo Co Ltd Conjugado de galnac-oligonucleotídeo para entrega ao fígado e método de fabricação do mesmo
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
EP4031140A1 (en) 2019-09-20 2022-07-27 F. Hoffmann-La Roche AG Method of treating hbv infection using a core protein allosteric modulator
WO2021074772A1 (en) 2019-10-14 2021-04-22 Astrazeneca Ab Modulators of pnpla3 expression
EP4045652A1 (en) 2019-10-18 2022-08-24 Alnylam Pharmaceuticals, Inc. Solute carrier family member irna compositions and methods of use thereof
MX2022004726A (es) 2019-10-22 2022-05-13 Alnylam Pharmaceuticals Inc Composiciones de acido ribonucleico de interferencia (arni) de componente c3 de complemento y metodos de uso de las mismas.
CA3155921A1 (en) 2019-11-01 2021-05-06 Alnylam Pharmaceuticals, Inc. HUNTINGTINE (HTT) TARGETING RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOF
PE20230179A1 (es) 2019-11-13 2023-02-01 Alnylam Pharmaceuticals Inc Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt)
WO2021102373A1 (en) 2019-11-22 2021-05-27 Alnylam Pharmaceuticals, Inc. Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
CN112876534B (zh) * 2019-11-29 2024-02-09 苏州瑞博生物技术股份有限公司 肝靶向化合物及缀合物
TWI897902B (zh) 2019-12-13 2025-09-21 美商阿尼拉製藥公司 人類染色體9開讀框72 (C9ORF72) iRNA劑組成物及其使用方法
WO2021126734A1 (en) 2019-12-16 2021-06-24 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
CN111041025B (zh) * 2019-12-17 2021-06-18 深圳市瑞吉生物科技有限公司 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法
JP2023506550A (ja) 2019-12-19 2023-02-16 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染症を処置するためのｓｂｄｓ阻害剤の使用
CN115516091A (zh) 2019-12-19 2022-12-23 豪夫迈·罗氏有限公司 Cops3抑制剂用于治疗乙型肝炎病毒感染的用途
CN114829599A (zh) 2019-12-19 2022-07-29 豪夫迈·罗氏有限公司 Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途
EP4077671A1 (en) 2019-12-19 2022-10-26 F. Hoffmann-La Roche AG Use of saraf inhibitors for treating hepatitis b virus infection
JP7634542B2 (ja) 2019-12-19 2025-02-21 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用
JP2023509870A (ja) 2019-12-24 2023-03-10 エフ． ホフマン－ラ ロシュ アーゲー Ｈｂｖの処置のためのｈｂｖを標的とする治療用オリゴヌクレオチドとｔｌｒ７アゴニストとの医薬組合せ
EP4081216A1 (en) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Method of treating virus infection using a tlr7 agonist
MX2022007909A (es) 2019-12-24 2022-07-21 Hoffmann La Roche Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
WO2021153687A1 (ja) 2020-01-30 2021-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 核酸複合体及びそれを含む医薬組成物
CN115427571A (zh) 2020-02-10 2022-12-02 阿尔尼拉姆医药品有限公司 沉默vegf-a表达的组合物和方法
JP7735288B2 (ja) 2020-02-18 2025-09-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用法
PH12022552258A1 (en) 2020-02-28 2023-11-20 Ionis Pharmaceuticals Inc Compounds and methods for modulating smn2
GB2629329B (en) 2020-03-04 2025-02-26 Verve Therapeutics Inc Formulation comprising GalNAc-lipid nanoparticle
WO2021178607A1 (en) 2020-03-05 2021-09-10 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
JP2023516095A (ja) 2020-03-06 2023-04-17 アルナイラム ファーマシューティカルズ， インコーポレイテッド ケトヘキソキナーゼ（ＫＨＫ）ｉＲＮＡ組成物およびその使用方法
KR20220152270A (ko) 2020-03-06 2022-11-15 알닐람 파마슈티칼스 인코포레이티드 트랜스티레틴 (ttr)의 발현을 억제하기 위한 조성물 및 방법
WO2021188611A1 (en) 2020-03-18 2021-09-23 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
EP4126967A1 (en) 2020-03-23 2023-02-08 Amgen Inc. Monoclonal antibodies to chemically-modified nucleic acids and uses thereof
CN116209759A (zh) 2020-03-26 2023-06-02 阿尔尼拉姆医药品有限公司 冠状病毒iRNA组合物及其使用方法
US20230113556A1 (en) * 2020-03-26 2023-04-13 National Cerebral And Cardiovascular Center Antisense nucleic acid targeting apoc3
IL297121A (en) 2020-04-06 2022-12-01 Alnylam Pharmaceuticals Inc Compositions and methods for silencing myoc expression
WO2021206917A1 (en) 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021207189A1 (en) 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing scn9a expression
EP4133077A1 (en) 2020-04-07 2023-02-15 Alnylam Pharmaceuticals, Inc. Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
BR112022021462A2 (pt) 2020-04-21 2023-01-17 Flagship Pioneering Inc Moléculas bifuncionais e métodos de sua utilização
CN111575279A (zh) * 2020-04-27 2020-08-25 江苏为真生物医药技术股份有限公司 利用asgpr小分子配体特异性捕获肝细胞外囊泡或循环肿瘤细胞的方法
MX2022013525A (es) 2020-04-27 2023-01-24 Alnylam Pharmaceuticals Inc Composiciones de agentes de ácido ribonucleico de interferencia (arni) de apolipoproteína e (apoe) y métodos de uso de las mismas.
JP2023523790A (ja) 2020-04-30 2023-06-07 アルナイラム ファーマシューティカルズ， インコーポレイテッド 補体因子Ｂ（ＣＦＢ）ｉＲＮＡ組成物およびその使用方法
EP4143321A4 (en) 2020-05-01 2025-02-19 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating atxn1
EP4150092A4 (en) 2020-05-11 2024-11-06 Stoke Therapeutics, Inc. OPA1 ANTISENSE OLIGOMERS FOR THE TREATMENT OF DISEASES AND CONDITIONS
EP4150089A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
WO2021231680A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
EP4150090A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of otoferlin (otof)
WO2021231673A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
EP4150077A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
WO2021231675A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
WO2021231679A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
WO2021231698A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
CN113683651A (zh) * 2020-05-19 2021-11-23 上海京新生物医药有限公司 一种GalNAc中间体的制备方法
AR122534A1 (es) 2020-06-03 2022-09-21 Triplet Therapeutics Inc Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
US20230203496A1 (en) 2020-06-09 2023-06-29 Alnylam Pharmaceuticals, Inc. Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
WO2021252557A1 (en) 2020-06-09 2021-12-16 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
WO2021249484A1 (zh) * 2020-06-10 2021-12-16 南京明德新药研发有限公司 缀合基团及其缀合物
MX2022015149A (es) 2020-06-18 2023-01-11 Alnylam Pharmaceuticals Inc Composiciones de acido ribonucleico de interferencia (arni) de xantina dehidrogenasa (xdh) y metodos de uso de las mismas.
CA3183885A1 (en) * 2020-06-24 2021-12-30 Ruben POSTEL Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
AR122731A1 (es) 2020-06-26 2022-10-05 Hoffmann La Roche Oligonucleótidos mejorados para modular la expresión de fubp1
JP2023532518A (ja) 2020-06-29 2023-07-28 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｐｌｐ１を調節するための化合物及び方法
CN111744019B (zh) 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 基于甘露糖的mRNA靶向递送系统及其应用
WO2022011262A1 (en) 2020-07-10 2022-01-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating epilepsy
IL299686A (en) 2020-07-28 2023-03-01 Ionis Pharmaceuticals Inc Compounds and methods for reducing app expression
BR112023002034A2 (pt) 2020-08-07 2023-04-04 Ionis Pharmaceuticals Inc Compostos e métodos para modulação de scn2a
CN116194119A (zh) * 2020-08-13 2023-05-30 美国安进公司 用于抑制MARC1表达的RNAi构建体和方法
CN116157522A (zh) 2020-08-21 2023-05-23 豪夫迈·罗氏有限公司 A1cf抑制剂用于治疗乙型肝炎病毒感染的用途
EP4217489A1 (en) 2020-09-24 2023-08-02 Alnylam Pharmaceuticals, Inc. Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
WO2022076291A1 (en) 2020-10-05 2022-04-14 Alnylam Pharmaceuticals, Inc. G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
CN116490195A (zh) 2020-10-16 2023-07-25 赛诺菲 用于抑制脂蛋白(a)的RNA组合物和方法
JP2023546103A (ja) 2020-10-16 2023-11-01 サノフイ Ａｎｇｐｔｌ３を阻害するための新規のｒｎａ組成物および方法
EP4232582A1 (en) 2020-10-23 2023-08-30 Alnylam Pharmaceuticals, Inc. Mucin 5b (muc5b) irna compositions and methods of use thereof
TW202237841A (zh) 2020-11-13 2022-10-01 美商艾拉倫製藥股份有限公司 凝血因子Ｖ（Ｆ５）ｉＲＮＡ組成物及其使用方法
TW202227101A (zh) 2020-11-18 2022-07-16 美商Ionis製藥公司 用於調節血管收縮素原表現之化合物及方法
CA3202708A1 (en) 2020-11-23 2022-05-27 Alpha Anomeric Sas Nucleic acid duplexes
WO2022125490A1 (en) 2020-12-08 2022-06-16 Alnylam Pharmaceuticals, Inc. Coagulation factor x (f10) irna compositions and methods of use thereof
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
CN116670280A (zh) 2020-12-18 2023-08-29 Ionis 制药公司 用于调节因子xii的化合物和方法
EP4237561A1 (en) 2020-12-23 2023-09-06 Argonaute Rna Limited Treatment of cardiovascular disease
US20250320500A1 (en) 2020-12-29 2025-10-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and sirna conjugate containing the nucleic acid, preparation method therefor, and use thereof
EP4274896A1 (en) 2021-01-05 2023-11-15 Alnylam Pharmaceuticals, Inc. Complement component 9 (c9) irna compositions and methods of use thereof
JP2024504504A (ja) * 2021-01-30 2024-01-31 イー セラピューティクス パブリック リミテッド カンパニー コンジュゲートオリゴヌクレオチド化合物、その作製方法及び使用
AU2022214281A1 (en) * 2021-01-30 2023-07-27 E-Therapeutics Plc Conjugated oligonucleotide compounds, methods of making and uses thereof
WO2022162157A1 (en) * 2021-01-30 2022-08-04 E-Therapeutics Plc Conjugated oligonucleotide compounds, methods of making and uses thereof
WO2022162161A1 (en) * 2021-01-30 2022-08-04 E-Therapeutics Plc Conjugated oligonucleotide compounds, methods of making and uses thereof
CN117355534A (zh) * 2021-01-30 2024-01-05 e-生物有限公司 缀合寡核苷酸化合物、其制备方法和用途
TW202246500A (zh) 2021-02-02 2022-12-01 瑞士商赫孚孟拉羅股份公司 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
WO2022174000A2 (en) 2021-02-12 2022-08-18 Alnylam Pharmaceuticals, Inc. Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
WO2022175749A1 (en) * 2021-02-18 2022-08-25 Oneglobe Holdings Limited Compositions for conjugating oligonucleotides and carbohydrates
WO2022182864A1 (en) 2021-02-25 2022-09-01 Alnylam Pharmaceuticals, Inc. Prion protein (prnp) irna compositions and methods and methods of use thereof
WO2022182574A1 (en) 2021-02-26 2022-09-01 Alnylam Pharmaceuticals, Inc. KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
IL305418A (en) 2021-03-04 2023-10-01 Alnylam Pharmaceuticals Inc Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
WO2022189861A1 (en) 2021-03-08 2022-09-15 Tollys Carbohydrate conjugates of tlr3 ligands and uses thereof
AU2022234522A1 (en) 2021-03-08 2023-10-26 Les Laboratoires Servier Antisense oligonucleotides for inhibiting alpha-synuclein expression
EP4305169A1 (en) 2021-03-12 2024-01-17 Alnylam Pharmaceuticals, Inc. Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
KR20230162024A (ko) 2021-03-29 2023-11-28 알닐람 파마슈티칼스 인코포레이티드 헌팅틴(HTT) iRNA 제제 조성물 및 이의 사용 방법
EP4314293A1 (en) 2021-04-01 2024-02-07 Alnylam Pharmaceuticals, Inc. Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
BR112023021109A2 (pt) 2021-04-14 2023-12-12 Dicerna Pharmaceuticals Inc Composições e métodos para modular a expressão de pnpla3
IL307926A (en) 2021-04-26 2023-12-01 Alnylam Pharmaceuticals Inc Transmembrane assemblies, serine 6 ((TMPRSS6 IRNA) and methods of using them
JP2024519293A (ja) 2021-04-29 2024-05-10 アルナイラム ファーマシューティカルズ， インコーポレイテッド シグナル伝達兼転写活性化因子６（ＳＴＡＴ６）ｉＲＮＡ組成物およびその使用方法
WO2022232650A1 (en) * 2021-04-30 2022-11-03 Ionis Pharmaceuticals, Inc. Methods for reducing agt expression
EP4341401A1 (en) 2021-05-18 2024-03-27 Alnylam Pharmaceuticals, Inc. Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
EP4341405A1 (en) 2021-05-20 2024-03-27 Korro Bio, Inc. Methods and compositions for adar-mediated editing
WO2022256283A2 (en) 2021-06-01 2022-12-08 Korro Bio, Inc. Methods for restoring protein function using adar
WO2022256395A1 (en) 2021-06-02 2022-12-08 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2022256290A2 (en) 2021-06-04 2022-12-08 Alnylam Pharmaceuticals, Inc. HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2022260939A2 (en) 2021-06-08 2022-12-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
TW202317765A (zh) 2021-06-18 2023-05-01 美商Ionis製藥公司 用於降低ｉｆｎａｒ１表現的化合物及方法
MX2023015523A (es) 2021-06-23 2024-03-11 Univ Massachusetts Compuestos de oligonucleotidos anti-flt1 optimizados para el tratamiento de la preeclampsia y otros desordenes angiogenicos.
MX2024000208A (es) * 2021-06-24 2024-01-29 Lilly Co Eli Restos de administracion terapeutica novedosos y usos de estos.
KR20240023630A (ko) * 2021-06-24 2024-02-22 일라이 릴리 앤드 캄파니 신규 rna 치료제 및 그의 용도
EP4363574A1 (en) 2021-06-29 2024-05-08 Korro Bio, Inc. Methods and compositions for adar-mediated editing
US20230194709A9 (en) 2021-06-29 2023-06-22 Seagate Technology Llc Range information detection using coherent pulse sets with selected waveform characteristics
IL309296A (en) 2021-06-30 2024-02-01 Alnylam Pharmaceuticals Inc Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
EP4365290A1 (en) * 2021-07-02 2024-05-08 Tuojie Biotech (Shanghai) Co., Ltd. Nucleic acid ligand and conjugate thereof, and preparation method therefor and use thereof
WO2023282346A1 (ja) 2021-07-08 2023-01-12 日本新薬株式会社 析出抑制剤
CN118475355A (zh) 2021-07-08 2024-08-09 日本新药株式会社 肾毒性减轻剂
EP4368176A4 (en) 2021-07-08 2025-06-25 Nippon Shinyaku Co., Ltd. Nephrotoxicity reducing agent
EP4373934A1 (en) 2021-07-19 2024-05-29 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
TW202325312A (zh) 2021-07-23 2023-07-01 美商艾拉倫製藥股份有限公司 β－鏈蛋白（ＣＴＮＮＢ１）ｉＲＮＡ組成物及其使用方法
JP2024529437A (ja) 2021-07-29 2024-08-06 アルナイラム ファーマシューティカルズ， インコーポレイテッド ３－ヒドロキシ－３－メチルグリタル－ＣＯＡレダクターゼ（ＨＭＧＣＲ）ｉＲＮＡ組成物およびその使用方法
CA3226651A1 (en) * 2021-08-03 2023-02-09 Kallanthottathil G. Rajeev Compositions and methods for targeted rna delivery
AR126675A1 (es) 2021-08-03 2023-11-01 Alnylam Pharmaceuticals Inc COMPOSICIONES DE ARNi CONTRA LA TRANSTIRRETINA (TTR) Y SUS MÉTODOS DE USO
WO2023014765A1 (en) 2021-08-04 2023-02-09 Alnylam Pharmaceuticals, Inc. iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
AU2022328347A1 (en) 2021-08-13 2024-02-08 Alnylam Pharmaceuticals, Inc. Factor xii (f12) irna compositions and methods of use thereof
MX2024002440A (es) 2021-08-31 2024-03-08 Alnylam Pharmaceuticals Inc Composiciones de acido ribonucleico de interferencia (arni) del efector b similar al factor de fragmentacion de adn subunidad alfa (dffa) que induce la muerte celular (cideb) y metodos de uso de estas.
CA3229020A1 (en) 2021-09-14 2023-03-23 Stella Khan Treatment of cardiovascular disease
EP4401742A2 (en) 2021-09-17 2024-07-24 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
EP4403633A1 (en) * 2021-09-18 2024-07-24 Genoval Therapeutics Co., Ltd. Lpa inhibitor and use thereof
JP2024535888A (ja) 2021-09-20 2024-10-02 アルナイラム ファーマシューティカルズ， インコーポレイテッド インヒビンサブユニットベータｅ（ｉｎｈｂｅ）モジュレーター組成物およびその使用方法
TW202327658A (zh) * 2021-09-23 2023-07-16 大陸商上海舶望製藥有限公司 具有二胺支架的用於靶向遞送治療劑的多價配體簇
KR20240082351A (ko) 2021-10-01 2024-06-10 아다르엑스 파마슈티컬스, 인크. 프리칼리크레인 조절 조성물 및 이의 사용 방법
US20250352667A1 (en) 2021-10-22 2025-11-20 Korro Bio, Inc. Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
AR127477A1 (es) 2021-10-29 2024-01-31 Alnylam Pharmaceuticals Inc COMPOSICIONES DE ARNi CONTRA EL FACTOR B DEL COMPLEMENTO (CFB) Y MÉTODOS DE USO DE LAS MISMAS
TW202334418A (zh) 2021-10-29 2023-09-01 美商艾拉倫製藥股份有限公司 杭丁頓（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
JP2024544532A (ja) 2021-11-11 2024-12-03 エフ． ホフマン－ラ ロシュ アーゲー Ｈｂｖの処置のための医薬組合せ
EP4441224A1 (en) 2021-12-03 2024-10-09 Quralis Corporation Gapmer antisense oligonucleotides with modified backbone chemistries
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
TW202340466A (zh) * 2021-12-16 2023-10-16 大陸商上海拓界生物醫藥科技有限公司 一種ｄｓｒｎａ、其製備方法及應用
TW202340465A (zh) * 2021-12-16 2023-10-16 大陸商上海拓界生物醫藥科技有限公司 靶向ｌｐａ的ｓｉｒｎａ及綴合物
CN119095603A (zh) 2021-12-17 2024-12-06 豪夫迈·罗氏有限公司 用于调节rtel1和fubp1的寡核苷酸的组合
CN118525092A (zh) * 2022-01-20 2024-08-20 上海拓界生物医药科技有限公司 一种dsRNA、其应用及制备方法
TW202345865A (zh) * 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
WO2023141314A2 (en) 2022-01-24 2023-07-27 Alnylam Pharmaceuticals, Inc. Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
EP4471140A1 (en) * 2022-01-30 2024-12-04 Rona Bioscience, Limited Targeting ligand containing n-acetylgalactosamine
AR128558A1 (es) 2022-02-21 2024-05-22 Hoffmann La Roche Oligonucleótido antisentido
TW202346589A (zh) 2022-03-10 2023-12-01 日商日本新藥股份有限公司 抗病毒反義寡聚物
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
US20250188477A1 (en) 2022-03-16 2025-06-12 Daiichi Sankyo Company, Limited CHEMICALLY MODIFIED OLIGONUCLEOTIDE HAVING RNAi ACTIVITY
CN118891366A (zh) 2022-03-16 2024-11-01 第一三共株式会社 抑制转铁蛋白受体2的表达的siRNA
IL315546A (en) 2022-03-16 2024-11-01 Empirico Inc GALNAC compositions to improve siRNA bioavailability
US12258563B2 (en) 2022-03-28 2025-03-25 Empirico Inc. Modified oligonucleotides
CN115028670B (zh) * 2022-06-24 2023-07-28 四川大学华西医院 一种n-乙酰基-d-半乳糖胺三聚体前体的制备方法
CN119654412A (zh) * 2022-06-27 2025-03-18 中美瑞康核酸技术(南通)研究院有限公司 激活补体因子h表达的寡核苷酸调节剂
CA3262119A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii Bv OLIGONUCLEOTIDES FOR ADAR-MEDIATED RNA EDITING AND THEIR USE
EP4555085A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Chemically modified oligonucleotides for adar-mediated rna editing
CN116814621B (zh) * 2022-08-05 2025-09-09 厦门甘宝利生物医药有限公司 一种抑制apoc3基因表达的rna抑制剂及其应用
EP4573198A2 (en) 2022-08-18 2025-06-25 Alnylam Pharmaceuticals, Inc. Universal non-targeting sirna compositions and methods of use thereof
WO2024059165A1 (en) 2022-09-15 2024-03-21 Alnylam Pharmaceuticals, Inc. 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
US12152052B2 (en) 2022-09-23 2024-11-26 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing MECP2 expression
WO2024098061A2 (en) 2022-11-04 2024-05-10 Genkardia Inc. Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
WO2024108217A1 (en) 2022-11-18 2024-05-23 Genkardia Inc. Methods and compositions for preventing, treating, or reversing cardiac diastolic dysfunction
WO2024106539A1 (ja) * 2022-11-18 2024-05-23 株式会社ボナック リガンドコンジュゲート物質及びそれを含む核酸並びにその用途
JP2025539851A (ja) * 2022-11-23 2025-12-09 プレッツェル セラピューティクス，インコーポレイテッド がん及び代謝疾患の治療のための組成物及び方法
PE20251853A1 (es) 2022-12-02 2025-07-22 Shanghai Argo Biopharmaceutical Co Ltd Analogos de acidos nucleicos biciclicos abasicos y compuestos oligomericos preparados a partir de estos
AU2023408479A1 (en) 2022-12-19 2025-05-01 Arnatar Therapeutics, Inc Advanced rna targeting (arnatar)
ES3030929T3 (en) 2022-12-19 2025-07-02 Arnatar Therapeutics Inc Arnatar compounds and methods for enhanced cellular uptake
AR131419A1 (es) * 2022-12-21 2025-03-19 Lilly Co Eli TERAPÉUTICOS NOVEDOSOS DE iARN DE FAS Y USOS DE ESTOS
KR20250134232A (ko) * 2023-01-10 2025-09-10 오스퍼바이오 테라퓨틱스 인크. 사용하기 위한 변형된 다중-세그먼트화 안티센스 올리고뉴클레오티드
IL322261A (en) 2023-02-09 2025-09-01 Alnylam Pharmaceuticals Inc Reverser molecules and methods of using them
WO2024175113A1 (zh) * 2023-02-24 2024-08-29 南京明德新药研发有限公司 包含R和E的双链siRNA类似物及其缀合物
AU2024258561A1 (en) 2023-04-20 2025-10-30 Adarx Pharmaceuticals, Inc. Mapt-modulating compositions and methods of use thereof
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods
WO2024221135A1 (en) * 2023-04-23 2024-10-31 Ausper Biopharma Co., Ltd. Oligonucleotides for use in modulating immune responses against hepatitis b viral infection
US20240374741A1 (en) * 2023-05-11 2024-11-14 Synerk Biotech Limited Compound, a conjugate and uses thereof
TW202502385A (zh) 2023-05-12 2025-01-16 美商雅迪克斯製藥公司 Ｎｍｄａ配位體結合之化合物及其用途
UY40743A (es) * 2023-05-19 2024-12-13 Shanghai Argo Biopharmaceutical Co Ltd COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN DEL factor de coagulación XI (FXI)
WO2024249328A2 (en) 2023-05-26 2024-12-05 Adarx Pharmaceuticals, Inc. Sod1-modulating compositions and methods of use thereof
AU2024280186A1 (en) * 2023-05-31 2025-12-04 Tuojie Biotech (Shanghai) Co., Ltd. Dsrna targeting lpa and use thereof
WO2024255761A1 (zh) * 2023-06-12 2024-12-19 大睿生物 包含糖的寡核苷酸递送配体
EP4562158A1 (en) 2023-06-13 2025-06-04 Arnatar Therapeutics, Inc Advanced rna targeting (arnatar) for angiotensinogen
WO2024263694A1 (en) 2023-06-20 2024-12-26 Adarx Pharmaceuticals, Inc. Lrrk2-modulating compositions and methods of use thereof
CN119219716A (zh) * 2023-06-30 2024-12-31 上海维申医药有限公司 新型GalNAc的靶向递送片段及其制备和应用
WO2025015335A1 (en) 2023-07-13 2025-01-16 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
WO2025015338A1 (en) 2023-07-13 2025-01-16 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
US20250051771A1 (en) * 2023-07-24 2025-02-13 Astrazeneca Ab Multivalent cargo-carrying complexes and uses thereof
GB202311334D0 (en) 2023-07-24 2023-09-06 Astrazeneca Ab Multivalent cargo-carrying complexes and uses thereof
GB202311324D0 (en) 2023-07-24 2023-09-06 Astrazeneca Ab Multivalent cargo-carrying complexes and uses thereof
WO2025034422A1 (en) 2023-08-04 2025-02-13 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating ctnnb1-associated disorders
WO2025036916A1 (en) 2023-08-16 2025-02-20 Les Laboratoires Servier Oligonucleotides for modulating kcnt1 expression
TW202511489A (zh) * 2023-08-31 2025-03-16 大陸商正大天晴藥業集團股份有限公司 靶向凝血因子ｘｉ的雙鏈核糖核酸
WO2025059466A1 (en) 2023-09-14 2025-03-20 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing apociii expression
CN116925160B (zh) * 2023-09-15 2023-12-08 天津全和诚科技有限责任公司 一种GalNAc含糖环中间体及其制备方法
WO2025064821A2 (en) * 2023-09-21 2025-03-27 Ionis Pharmaceuticals, Inc. Compounds and methods for inhibiting lpa
WO2025064819A1 (en) * 2023-09-21 2025-03-27 Ionis Pharmaceuticals, Inc. Compounds and methods for inhibiting lpa
GB202314724D0 (en) 2023-09-26 2023-11-08 Astrazeneca Ab compounds and methods for reducing psd3 expression
WO2025072748A2 (en) * 2023-09-29 2025-04-03 Insitro, Inc. Compositions and methods for treating nonalcoholic fatty liver disease
CN118680948B (zh) * 2023-10-20 2025-08-22 思合基因(北京)生物科技有限公司 寡核苷酸及其在抗乙型肝炎病毒中的应用
WO2025096809A1 (en) 2023-10-31 2025-05-08 Korro Bio, Inc. Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025113470A1 (en) * 2023-11-27 2025-06-05 Shanghai Argo Biopharmaceutical Co., Ltd. Compositions and methods for inhibiting expression of transthyretin (ttr)
CN120098993A (zh) * 2023-12-05 2025-06-06 广东东阳光药业股份有限公司 一种新型的双链siRNA、其缀合物及其用途
CN120309684A (zh) * 2024-01-15 2025-07-15 武汉人福创新药物研发中心有限公司 靶向化合物及其用途
CN117568313B (zh) * 2024-01-15 2024-04-26 上海贝斯昂科生物科技有限公司 基因编辑组合物及其用途
WO2025155911A1 (en) 2024-01-18 2025-07-24 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of hurler syndrome
WO2025165891A1 (en) 2024-01-29 2025-08-07 Arnatar Therapeutics, Inc Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
US20250297260A1 (en) 2024-03-22 2025-09-25 Takeda Pharmaceutical Company Limited Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease
CN118146284B (zh) * 2024-05-08 2024-07-26 北京悦康科创医药科技股份有限公司 一种GalNAc化合物、其与寡核苷酸缀合物及制备方法
WO2025242702A1 (en) * 2024-05-23 2025-11-27 Glaxosmithkline Intellectual Property Development Limited Enzymatic process for producing n-acetyl galactosamine clusters

Family Cites Families (380)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
DE3329892A1 (de) 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg Verfahren zur herstellung von oligonucleotiden
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
USRE34036E (en) 1984-06-06 1992-08-18 National Research Development Corporation Data transmission using a transparent tone-in band system
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US4751219A (en) 1985-02-05 1988-06-14 Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
EP0260032B1 (en) 1986-09-08 1994-01-26 Ajinomoto Co., Inc. Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
GB8712540D0 (en) * 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
AU598946B2 (en) 1987-06-24 1990-07-05 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5403711A (en) 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
WO1989005358A1 (en) 1987-11-30 1989-06-15 University Of Iowa Research Foundation Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
WO1989009221A1 (en) 1988-03-25 1989-10-05 University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5721218A (en) 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
ATE190981T1 (de) 1989-10-24 2000-04-15 Isis Pharmaceuticals Inc 2'-modifizierte nukleotide
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5859221A (en) 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5623065A (en) 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ES2116977T3 (es) 1990-05-11 1998-08-01 Microprobe Corp Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente.
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5223618A (en) 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
BR9106702A (pt) 1990-07-27 1993-06-08 Isis Pharmaceuticals Inc Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
NZ239247A (en) 1990-08-03 1993-11-25 Sterling Drug Inc Oligonucleosides containing a non-phosphate inter nucleoside linkage
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
WO1992005186A1 (en) 1990-09-20 1992-04-02 Gilead Sciences Modified internucleoside linkages
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5948903A (en) 1991-01-11 1999-09-07 Isis Pharmaceuticals, Inc. Synthesis of 3-deazapurines
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
DE59208572D1 (de) 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
CA2122365C (en) 1991-11-26 2010-05-11 Brian Froehler Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
DK0618925T4 (da) * 1991-12-24 2012-07-09 Isis Pharmaceuticals Inc Antisense-oligonukleotider
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
JPH08502723A (ja) * 1992-07-27 1996-03-26 ハイブライドン インコーポレイテッド オリゴヌクレオチド・アルキルホスホノチオエート
EP0673559A1 (en) 1992-12-14 1995-09-27 Honeywell Inc. Motor system with individually controlled redundant windings
CA2154578A1 (en) 1993-01-25 1994-08-04 Ekambar R. Kandimalla Oligonucleotide alkylphosphonates and alkylphosphonothioates
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
GB9304620D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Compounds
JPH08508492A (ja) 1993-03-30 1996-09-10 スターリング ウィンスロップ インコーポレイティド 非環式ヌクレオシド類似体及びそれらを含むオリゴヌクレオチド配列
DE69407032T2 (de) 1993-03-31 1998-07-02 Sanofi Sa Oligonucleotide mit amidverkettungen die phosphoesterverkettungen einsetzen
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
PT733059E (pt) 1993-12-09 2001-03-30 Univ Jefferson Compostos e metodos para mutacoes dirigidas ao local em celulas eucarioticas
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5728518A (en) 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5646269A (en) 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
US5681940A (en) * 1994-11-02 1997-10-28 Icn Pharmaceuticals Sugar modified nucleosides and oligonucleotides
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US5652356A (en) 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
EP0862439A4 (en) 1995-11-22 2001-01-10 O Paul O P Ts LIGANDS FOR INCREASING THE CELLULAR UPtake OF BIOMOLECULES
US20030119724A1 (en) 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
CN1231675A (zh) 1996-09-26 1999-10-13 味之素株式会社 修饰的生理活性蛋白及含有该蛋白的药物组合物
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
ATE293123T1 (de) 1997-09-12 2005-04-15 Exiqon As Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
US20040171564A1 (en) 1997-11-20 2004-09-02 Honkanen Richard E. Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6300319B1 (en) 1998-06-16 2001-10-09 Isis Pharmaceuticals, Inc. Targeted oligonucleotide conjugates
US6043352A (en) 1998-08-07 2000-03-28 Isis Pharmaceuticals, Inc. 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
RU2249463C2 (ru) * 1998-08-19 2005-04-10 Бакстер Хелфкэа С.А. Иммуногенный конъюгат бета-пропионамид-связанного полисахарида с белком, использующийся в качестве вакцины
CA2340692A1 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. Immunogenic .beta.-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
US6166239A (en) 1998-09-04 2000-12-26 Isis Pharmaceuticals, Inc. Oligonucleotide protecting groups
DK1152009T4 (en) 1999-02-12 2017-12-11 Daiichi Sankyo Co Ltd HIS UNKNOWN NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGS
US20030170249A1 (en) 1999-02-19 2003-09-11 Hakomori Sen-Itiroh Vaccines directed to cancer-associated carbohydrate antigens
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US6159694A (en) 1999-04-08 2000-12-12 Isis Pharmaceuticals Inc. Antisense modulation of stat3 expression
JP2002542263A (ja) 1999-04-21 2002-12-10 ワイス ポリヌクレオチド配列の機能を阻害するための方法および組成物
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US6383812B1 (en) 1999-05-28 2002-05-07 Academia Sinica Anti liver disease drug R-YEEE and method of synthesizing branched galactose-terminal glycoproteins
US20080281041A1 (en) 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
US8541548B2 (en) 1999-06-07 2013-09-24 Arrowhead Madison Inc. Compounds and methods for reversible modification of biologically active molecules
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
EP1210363A2 (en) 1999-07-16 2002-06-05 Hyseq, Inc. Novel angiopoietin materials and methods
JP4151751B2 (ja) 1999-07-22 2008-09-17 第一三共株式会社 新規ビシクロヌクレオシド類縁体
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
US20020082227A1 (en) 1999-09-30 2002-06-27 Scott Henry Use of oligonucleotides for inhibition of complement activation
US20050112118A1 (en) 1999-12-02 2005-05-26 Myriad Genetics, Incorporated Compositions and methods for treating inflammatory disorders
CZ20021853A3 (cs) 1999-12-09 2002-11-13 Sankyo Company, Limited Způsob testování účinku látky, polynukleotid, DNA, protilátka, souprava pro testování, pouľití polynukleotidu, pouľití polypeptidu, pouľití protilátky, RNA a terapeutické činidlo
WO2001049687A2 (en) 1999-12-30 2001-07-12 K. U. Leuven Research & Development Cyclohexene nucleic acids
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US7179796B2 (en) 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US6602857B1 (en) 2000-01-18 2003-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
AU2001241541A1 (en) 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
EP1314734A1 (en) 2000-08-29 2003-05-28 Takeshi Imanishi Novel nucleoside analogs and oligonucleotide derivatives containing these analogs
US6426220B1 (en) 2000-10-30 2002-07-30 Isis Pharmaceuticals, Inc. Antisense modulation of calreticulin expression
EP1355672A2 (en) 2000-12-01 2003-10-29 Cell Works Inc. Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
IL159153A0 (en) 2001-06-08 2004-06-01 Sankyo Co Methods for testing drugs for treating or preventing diseases such as hyperlipidemia
US20030175906A1 (en) 2001-07-03 2003-09-18 Muthiah Manoharan Nuclease resistant chimeric oligonucleotides
US20030158403A1 (en) 2001-07-03 2003-08-21 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
WO2003004602A2 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US7425545B2 (en) * 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
WO2003014397A1 (en) 2001-08-09 2003-02-20 Biomedlab Corporation Probe for detection of enteric virus detection kit and method for enteric virus with the same
WO2003020739A2 (en) 2001-09-04 2003-03-13 Exiqon A/S Novel lna compositions and uses thereof
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
EP1451578B1 (en) 2001-11-16 2013-08-21 Genentech, Inc. Use of angptl3 antagonists for the treatment of liver diseases
US20100240730A1 (en) 2002-02-20 2010-09-23 Merck Sharp And Dohme Corp. RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA)
US20050239728A1 (en) 2002-07-31 2005-10-27 Pachuk Catherine J Double stranded rna structures and constructs, and methods for generating and using the same
US8729036B2 (en) 2002-08-07 2014-05-20 University Of Massachusetts Compositions for RNA interference and methods of use thereof
WO2004024757A2 (en) 2002-09-11 2004-03-25 Santaris Pharma A/S Modified pna molecules
AU2003284323A1 (en) 2002-10-18 2004-05-04 Alnylam Pharmaceuticals Inc Double-stranded rna structures and constructs, and methods for generating and using the same
WO2004044133A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
US7696345B2 (en) 2002-11-05 2010-04-13 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20060009410A1 (en) 2002-11-13 2006-01-12 Crooke Rosanne M Effects of apolipoprotein B inhibition on gene expression profiles in animals
JP4986109B2 (ja) 2002-11-13 2012-07-25 ジェンザイム・コーポレーション アポリポタンパク質ｂ発現のアンチセンス調節
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
ATE517992T1 (de) 2002-11-14 2011-08-15 Dharmacon Inc Funktionelle und hyperfunktionelle sirna
JP5479663B2 (ja) 2002-12-20 2014-04-23 セレラ コーポレーション 心筋梗塞に関連する遺伝的多型、その検出方法および使用
US6673661B1 (en) 2002-12-20 2004-01-06 Taiwan Semiconductor Manufacturing Co., Ltd. Self-aligned method for forming dual gate thin film transistor (TFT) device
WO2004063208A1 (en) 2003-01-09 2004-07-29 Postech Foundation New phosphoramidite compounds
WO2004072046A2 (en) 2003-02-12 2004-08-26 Carex S.A. Quinoline derivatives and their use for modulation of lxr activity
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
WO2004080406A2 (en) 2003-03-07 2004-09-23 Alnylam Pharmaceuticals Therapeutic compositions
EP1608735A4 (en) * 2003-04-03 2008-11-05 Alnylam Pharmaceuticals RNAI CONJUGATES
US7598227B2 (en) * 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
JP4597976B2 (ja) 2003-04-17 2010-12-15 アルナイラム ファーマシューティカルズ インコーポレイテッド 修飾ｉＲＮＡ剤
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
US7750142B2 (en) 2003-04-28 2010-07-06 Isis Pharmaceuticals, Inc. Modulation of glucagon receptor expression
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
JPWO2004101619A1 (ja) 2003-05-15 2006-10-26 塩野義製薬株式会社 機能的糖ペプチドの合理的設計および合成
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
CA2539181A1 (en) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. Modulation of eif4e expression
AU2004274021B2 (en) 2003-09-18 2009-08-13 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
US8258105B2 (en) * 2003-10-07 2012-09-04 Isis Pharmaceuticals, Inc. Antisense oligonucleotides optimized for kidney targeting
US7959919B2 (en) 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
WO2005065686A1 (en) 2004-01-07 2005-07-21 Adipogen Pharmaceuticals Pty Limited Differentiation modulating agents and uses therefor
EP2363480A3 (en) 2004-01-20 2015-10-07 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
WO2005075453A1 (ja) * 2004-02-05 2005-08-18 Japan Science And Technology Agency リンカー化合物及びリガンド複合体、並びにそれらの製造方法
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
JPWO2005097155A1 (ja) 2004-04-08 2008-02-28 タカラバイオ株式会社 神経突起伸長誘導剤
KR20070085113A (ko) 2004-05-11 2007-08-27 가부시키가이샤 알파젠 Rna간섭을 생기게 하는 폴리뉴클레오티드, 및 이를 이용한유전자발현억제 방법
CA2568735A1 (en) 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
EP2172482A1 (en) 2004-07-20 2010-04-07 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US7371384B2 (en) 2004-07-20 2008-05-13 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein antibody
JP5192234B2 (ja) 2004-08-10 2013-05-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド 化学修飾オリゴヌクレオチド
SI2409713T1 (sl) * 2004-08-10 2015-10-30 Genzyme Corporation Oligonukleotidi za uporabo pri uravnavanju nivojev lipoproteinov in holesterola pri ljudeh
WO2006031461A2 (en) 2004-09-09 2006-03-23 Isis Pharmaceuticals, Inc. Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
US20090036355A1 (en) 2004-10-13 2009-02-05 Sanjay Bhanot Antisense Modulation of PTP1B Expression
EP1812569A2 (en) 2004-11-08 2007-08-01 K.U. Leuven Research and Development Modified nucleosides for rna interference
US20060148740A1 (en) 2005-01-05 2006-07-06 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
EP1841867A1 (en) 2005-01-24 2007-10-10 Avaris AB COMPLEX CONTAINING SiRNA, ShRNA OR ANTISENSE MOLECULE AND FUNCTIONAL ENTITY, FOR IMPROVED SPECIFICITY AND DELIVERY
KR20080068019A (ko) * 2005-09-15 2008-07-22 산타리스 팔마 에이/에스 아포지단백질-ｂ100 발현 억제용 ｒｎａ 길항제 화합물
EP2388326A1 (en) 2005-09-19 2011-11-23 Isis Pharmaceuticals, Inc. Modulation of glucagon receptor expression
KR20080065617A (ko) 2005-09-19 2008-07-14 존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨 글루코코티코이드 수용체 발현의 조절
ES2453380T3 (es) * 2006-01-26 2014-04-07 Isis Pharmaceuticals, Inc. Composiciones y utilizaciones dirigidas hacia la huntingtina
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
AU2007211080B9 (en) 2006-01-27 2012-05-03 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
CN101553236A (zh) * 2006-05-05 2009-10-07 埃西斯药品公司 调节gccr的表达的化合物和方法
US8586554B2 (en) 2006-05-05 2013-11-19 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of PTP1B
WO2007134181A2 (en) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
JP2010500290A (ja) 2006-08-04 2010-01-07 アイシス ファーマシューティカルズ， インコーポレーテッド Ｊｎｋタンパク質を調節するための組成物および方法
EP2061443A4 (en) 2006-08-18 2013-07-24 Arrowhead Res Corp POLYCONJUGATE FOR IN VIVO ADMINISTRATION OF POLYNUCLEOTIDES
US8658211B2 (en) 2006-08-18 2014-02-25 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
WO2008036825A2 (en) 2006-09-22 2008-03-27 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by rna interference
CA2667055C (en) 2006-10-18 2017-05-09 Isis Pharmaceuticals, Inc. Antisense compounds
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
TW200838551A (en) 2006-11-27 2008-10-01 Isis Pharmaceuticals Inc Methods for treating hypercholesterolemia
CN101855241B (zh) 2006-12-08 2013-11-06 莱克康制药公司 针对angptl3的单克隆抗体
CA2839162A1 (en) * 2006-12-20 2008-06-26 Xoma Technology Ltd. Methods for the treatment of il-1-.beta. related diseases
WO2008101157A1 (en) 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
US9216228B2 (en) 2007-02-16 2015-12-22 KTB Tumorforschungsgesellschaft MBM Receptor and antigen targeted prodrug
EP2134173A4 (en) 2007-03-01 2010-11-10 Wellstat Ophthalmics Corp TREATMENT OF DISEASES SIGNED BY IGNITION
JP2010519911A (ja) 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド Ｍｙｃ遺伝子の発現を抑制するための核酸化合物およびその使用
WO2008131419A2 (en) 2007-04-23 2008-10-30 Alnylam Pharmaceuticals, Inc. Glycoconjugates of rna interference agents
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US8278426B2 (en) 2007-06-08 2012-10-02 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
US20090004140A1 (en) 2007-06-26 2009-01-01 Yao-Ling Qiu 4-substituted pyrrolidine as anti-infectives
CN101796062B (zh) 2007-07-05 2014-07-30 Isis制药公司 6-双取代双环核酸类似物
AU2008286771B2 (en) 2007-08-15 2013-08-15 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
WO2009024977A2 (en) * 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
NZ584827A (en) * 2007-10-01 2012-10-26 Isis Pharmaceuticals Inc Antisense modulation of fibroblast growth factor receptor 4 expression
BRPI0820391A2 (pt) 2007-11-09 2015-05-19 Isis Pharmaceutical Inc Composto, composição e métodos de modulação da expressão do fator 7
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
US20090247608A1 (en) * 2007-12-04 2009-10-01 Alnylam Pharmaceuticals, Inc. Targeting Lipids
KR101926292B1 (ko) * 2007-12-27 2018-12-06 가부시끼가이샤 스텔릭 사이세이 이카가꾸 겐뀨쇼 당쇄 관련 유전자, 및 그의 이용
BRPI0907008A2 (pt) 2008-01-31 2015-07-07 Alnylam Pharmaceuticals Inc Métodos otimizados para liberação de dsrna alvejando o gene pcsk9
WO2009100320A2 (en) 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2009120878A2 (en) 2008-03-26 2009-10-01 Alnylam Pharmaceuticals, Inc. Non-natural ribonucleotides, and methods of use thereof
AU2009234266B2 (en) 2008-04-11 2015-08-06 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
WO2009143369A2 (en) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc. Method of preparing nucleosides and analogs thereof without using chromatography
WO2009148605A2 (en) 2008-06-04 2009-12-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
EP2733222A1 (en) 2008-07-09 2014-05-21 Celera Corporation Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
EP2323667A4 (en) 2008-08-07 2012-07-25 Isis Pharmaceuticals Inc MODULATION OF TRANSTHYRETIN EXPRESSION BY TREATMENT OF CNS DISEASES
CA2737661C (en) 2008-09-23 2019-08-20 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
EP2361256B1 (en) 2008-09-24 2013-04-10 Isis Pharmaceuticals, Inc. Cyclohexenyl nucleic acid analogs
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
KR101979134B1 (ko) 2008-10-15 2019-05-15 아이오니스 파마수티컬즈, 인코포레이티드 인자 １１ 발현의 조정
CN106834291B (zh) * 2008-10-20 2020-09-29 阿尔尼拉姆医药品有限公司 抑制运甲状腺素蛋白表达的组合物和方法
WO2010048549A2 (en) 2008-10-24 2010-04-29 Isis Pharmaceuticals, Inc. 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
WO2010048585A2 (en) 2008-10-24 2010-04-29 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
JP5832898B2 (ja) 2008-11-10 2015-12-16 テクミラ ファーマシューティカルズ コーポレイションＴｅｋｍｉｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 治療薬を送達するための新規な脂質及び組成物
US9023820B2 (en) 2009-01-26 2015-05-05 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein C-III expression
CA2751342C (en) 2009-01-29 2019-05-07 Alnylam Pharmaceuticals, Inc. Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
EP3424939A1 (en) 2009-03-02 2019-01-09 Alnylam Pharmaceuticals Inc. Nucleic acid chemical modifications
FR2943060B1 (fr) 2009-03-13 2013-01-04 Commissariat Energie Atomique Agents chelatants d'ions metalliques, leurs procedes de preparation et leurs applications
WO2010121074A1 (en) 2009-04-15 2010-10-21 Isis Pharmaceuticals, Inc. Modulation of inflammatory responses by factor xi
SG10201911942UA (en) 2009-05-05 2020-02-27 Muthiah Manoharan Lipid compositions
JP5875976B2 (ja) 2009-06-01 2016-03-02 ヘイロー−バイオ アールエヌエーアイ セラピューティクス， インコーポレイテッド 多価ｒｎａ干渉のためのポリヌクレオチド、組成物およびそれらの使用方法
SG10201912450XA (en) 2009-06-10 2020-03-30 Arbutus Biopharma Corp Improved lipid formulation
CN104651408A (zh) 2009-06-15 2015-05-27 阿尔尼拉姆医药品有限公司 靶向pcsk9基因的脂质配制的dsrna
CA2767225A1 (en) 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for enhancing production of a biological product
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US9512164B2 (en) 2009-07-07 2016-12-06 Alnylam Pharmaceuticals, Inc. Oligonucleotide end caps
US20120214862A1 (en) 2009-07-16 2012-08-23 Isis Pharmaceuticals, Inc. Modulation of factor 7 expression
WO2011017521A2 (en) 2009-08-06 2011-02-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US8901072B2 (en) * 2009-08-12 2014-12-02 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility
TWI458493B (zh) 2009-09-25 2014-11-01 Iner Aec Executive Yuan 新穎肝標靶藥劑與合成方法
BR112012008865A2 (pt) 2009-10-16 2019-09-24 Glaxo Group Ltd inibidores de hbv anti-sentido.
TWI391144B (zh) 2009-10-26 2013-04-01 Iner Aec Executive Yuan 一種定量肝殘餘功能的檢驗方法與其新穎肝受體造影檢驗藥劑
TWI388338B (zh) 2009-10-26 2013-03-11 Iner Aec Executive Yuan 對聚合醣鏈進行放射標誌以作為肝受體造影劑之方法
JP5723378B2 (ja) * 2009-11-03 2015-05-27 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トランスサイレチン（ｔｔｒ）を阻害する脂質製剤化組成物及び方法
WO2011072290A2 (en) 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
EP2521556B1 (en) 2010-01-08 2018-05-30 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
WO2011100131A2 (en) 2010-01-28 2011-08-18 Alnylam Pharmacuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
JP6137834B2 (ja) 2010-02-24 2017-05-31 アローヘッド ファーマシューティカルズ インコーポレイテッド ｓｉＲＮＡの標的化送達のための組成物
US9193752B2 (en) 2010-03-17 2015-11-24 Isis Pharmaceuticals, Inc. 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2553019A1 (en) 2010-03-26 2013-02-06 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
US20130109817A1 (en) 2010-03-26 2013-05-02 Mersana Therapeutics, Inc. Modified Polymers for Delivery of Polynucleotides, Method of Manufacture, and Methods of Use Thereof
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
WO2011133876A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
EP2601204B1 (en) 2010-04-28 2016-09-07 Ionis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
EP3091027B1 (en) 2010-04-28 2018-01-17 Ionis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
ES2625689T3 (es) 2010-04-29 2017-07-20 Ionis Pharmaceuticals, Inc. Modulación de la expresión de transtiretina
US20130236968A1 (en) 2010-06-21 2013-09-12 Alnylam Pharmaceuticals, Inc. Multifunctional copolymers for nucleic acid delivery
JP2013541334A (ja) 2010-09-15 2013-11-14 アルニラム ファーマスーティカルズ インコーポレイテッド 修飾されたｉＲＮＡ剤
WO2012067970A2 (en) 2010-11-11 2012-05-24 Ted M Dawson Transcriptional repression leading to parkinson's disease
US8987377B2 (en) 2010-11-19 2015-03-24 Alnylam Pharmaceuticals, Inc. Poly(amide) polymers for the delivery of oligonucleotides
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
US9249179B2 (en) 2010-12-17 2016-02-02 Arrowhead Madison Inc. Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA
EP2658981B1 (en) 2010-12-29 2016-09-28 F.Hoffmann-La Roche Ag Small molecule conjugates for intracellular delivery of nucleic acids
WO2012109395A1 (en) 2011-02-08 2012-08-16 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2012135736A2 (en) 2011-04-01 2012-10-04 Isis Pharmaceuticals, Inc. Modulation of signal transducer and activator of transcription 3 (stat3) expression
JP5951752B2 (ja) 2011-04-13 2016-07-13 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｐｔｐ１ｂ発現のアンチセンス調節
SG194555A1 (en) 2011-04-21 2013-12-30 Isis Pharmaceuticals Inc Modulation of hepatitis b virus (hbv) expression
TW201303013A (zh) 2011-04-21 2013-01-16 Isis Pharmaceuticals Inc Ｂ型肝炎病毒（ｈｂｖ）表現之調節
WO2012149495A1 (en) 2011-04-27 2012-11-01 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein ciii (apociii) expression
WO2012174154A1 (en) 2011-06-13 2012-12-20 Isis Pharmaceuticals, Inc. Modulation of inflammatory responses by factor vii
CA2839437A1 (en) * 2011-06-16 2012-12-20 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
EP4092120A1 (en) 2011-06-21 2022-11-23 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (anglptl3) irna compositions and methods of use thereof
KR102540778B1 (ko) 2011-06-21 2023-06-07 알닐람 파마슈티칼스 인코포레이티드 아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
WO2012177639A2 (en) 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
US20130017250A1 (en) 2011-07-15 2013-01-17 The Trustees Of Columbia University In The City Of New York Methods For High Density Lipoprotein Cholesterol Regulation
CA2842039A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
US10023861B2 (en) 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
AU2012312433B2 (en) 2011-09-20 2017-07-06 Ionis Pharmaceuticals, Inc. Antisense modulation of GCGR expression
US8901098B2 (en) 2011-10-25 2014-12-02 Isis Pharmaceuticals, Inc. Antisense modulation of GCCR expression
PT3301177T (pt) 2011-11-18 2020-06-29 Alnylam Pharmaceuticals Inc Agentes de arni, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
US20150031747A1 (en) 2012-02-08 2015-01-29 Isis Pharmaceuticals, Inc. Methods and compositions for modulating factor vii expression
WO2013142514A1 (en) 2012-03-19 2013-09-26 Isis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
WO2013142571A2 (en) 2012-03-20 2013-09-26 Cornell University Assays for the identification of compounds that modulate lipid homeostasis
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
WO2013159109A1 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
WO2013159108A2 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
TWI595885B (zh) 2012-05-02 2017-08-21 喜納製藥公司 包含四ｇａｌｎａｃ之新穎結合物及傳送寡核苷酸之方法
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
RU2624028C2 (ru) 2012-05-24 2017-06-30 Ионис Фармасьютикалз, Инк. Способы и композиции для модулирования экспрессии аполипопротеина (а)
WO2013192233A1 (en) 2012-06-18 2013-12-27 Isis Pharmaceuticals, Inc. Compounds and method for improved cellular uptake of antisense compounds
CN104717982B (zh) 2012-08-06 2018-08-28 阿尔尼拉姆医药品有限公司 碳水化合物共轭物及其制备改进工艺
WO2014059353A2 (en) 2012-10-11 2014-04-17 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and uses thereof
EP3406718A1 (en) 2012-11-15 2018-11-28 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
RU2649367C2 (ru) 2013-01-30 2018-04-02 Ф. Хоффманн-Ля Рош Аг Конъюгаты углевода и lna-олигонуклеотида
CN105378082B (zh) * 2013-05-01 2020-06-09 Ionis制药公司 组合物和方法
AU2013389474B2 (en) 2013-05-16 2018-11-15 Racthera Co., Ltd. Transplantation adjuvant in cell therapy using neural progenitor cells
EP3730619A1 (en) 2013-06-21 2020-10-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
WO2014207232A1 (en) 2013-06-27 2014-12-31 Santaris Pharma A/S Antisense oligomers and conjugates targeting pcsk9
EP3730614A3 (en) 2013-07-02 2020-12-30 Ionis Pharmaceuticals, Inc. Modulators of growth hormone receptor
EP3019200B1 (en) 2013-07-11 2022-03-23 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
PT3043827T (pt) 2013-09-13 2019-09-26 Ionis Pharmaceuticals Inc Moduladores do fator b do complemento
US9943604B2 (en) 2013-09-20 2018-04-17 Ionis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
RU2016122168A (ru) 2013-11-14 2017-12-19 Рош Инновейшен Сентер Копенгаген А/С Антисмысловые конъюгаты, направленные на аполипопротеин b
US10150965B2 (en) 2013-12-06 2018-12-11 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
JP6482475B2 (ja) * 2014-01-07 2019-03-13 レナセラピューティクス株式会社 アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
EP3811977B1 (en) 2014-05-01 2025-12-03 Ionis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
PL3137605T3 (pl) 2014-05-01 2021-04-19 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji białka angiopoetynopodobnego 3
CA2943894A1 (en) 2014-05-01 2015-11-05 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating complement factor b expression
ES2812099T3 (es) 2014-05-01 2021-03-16 Ionis Pharmaceuticals Inc Composiciones y métodos para modular la expresión del receptor de la hormona del crecimiento
MX377141B (es) 2014-05-01 2025-03-07 Ionis Pharmaceuticals Inc Composiciones y metodos para modular la expresion de pkk.
WO2015179693A1 (en) 2014-05-22 2015-11-26 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
WO2015188194A1 (en) 2014-06-06 2015-12-10 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds
CN113952353A (zh) * 2015-11-06 2022-01-21 Ionis制药公司 调节载脂蛋白(a)表达
PL4119569T3 (pl) * 2015-11-06 2024-11-18 Ionis Pharmaceuticals, Inc. Sprzężone związki antysensowne do zastosowania w terapii

Also Published As

Publication number Publication date
AU2020217347A1 (en) 2020-08-27
EA201891479A1 (ru) 2018-11-30
US20150126719A1 (en) 2015-05-07
CA2921514A1 (en) 2014-11-06
NZ740338A (en) 2022-04-29
EP3524680A1 (en) 2019-08-14
KR20160002974A (ko) 2016-01-08
SI2992009T1 (sl) 2020-10-30
EP3546579A1 (en) 2019-10-02
EP2991661A4 (en) 2017-02-15
RU2015151203A (ru) 2017-06-02
PH12019501191A1 (en) 2021-03-01
JP2016522817A (ja) 2016-08-04
KR20240147701A (ko) 2024-10-08
KR102138781B1 (ko) 2020-07-28
US20220275365A9 (en) 2022-09-01
CN105377887B (zh) 2020-11-03
IL242126B (en) 2019-01-31
DK3524680T3 (da) 2020-12-14
US20150126718A1 (en) 2015-05-07
RU2015151199A (ru) 2017-06-05
CL2016002262A1 (es) 2017-06-09
US9932580B2 (en) 2018-04-03
CN110066795A (zh) 2019-07-30
US20240247260A1 (en) 2024-07-25
BR112015027321A2 (pt) 2017-09-26
CA2921509C (en) 2025-10-07
JP2019056001A (ja) 2019-04-11
JP2023012548A (ja) 2023-01-25
JP2021020901A (ja) 2021-02-18
DK2992009T3 (da) 2020-09-14
IL264580A (en) 2019-02-28
EP2992009A4 (en) 2016-12-28
FIC20250028I1 (fi) 2025-08-18
IL273184B (en) 2021-07-29
AU2019202598A1 (en) 2019-05-02
NZ631537A (en) 2017-05-26
JP6769866B2 (ja) 2020-10-14
AU2024266799A1 (en) 2024-12-12
WO2014179629A8 (en) 2016-06-02
EP4438129A2 (en) 2024-10-02
KR20210151260A (ko) 2021-12-13
KR20240042220A (ko) 2024-04-01
WO2014179627A2 (en) 2014-11-06
KR20200090966A (ko) 2020-07-29
US10844379B2 (en) 2020-11-24
CA2921514C (en) 2023-10-24
EP3828275A1 (en) 2021-06-02
CN111593051A (zh) 2020-08-28
WO2014179627A3 (en) 2015-04-16
EP2992098A4 (en) 2017-01-11
IL284000A (en) 2021-07-29
IL261901B (en) 2020-05-31
JP2020039355A (ja) 2020-03-19
IL296543B1 (en) 2024-10-01
CY1121879T1 (el) 2020-10-14
MX381034B (es) 2025-04-01
RU2015151204A (ru) 2017-06-02
EP3524680B1 (en) 2020-11-11
MX2019010443A (es) 2019-10-17
MX2015015220A (es) 2016-01-12
MY198359A (en) 2023-08-28
MX2015015263A (es) 2016-12-16
SG10201906382QA (en) 2019-08-27
CN114058617A (zh) 2022-02-18
MX2021008899A (es) 2021-08-19
AU2017203436B2 (en) 2018-10-18
MA60161A1 (fr) 2024-09-30
BR112015027369B1 (pt) 2021-06-08
BR112015027319A2 (pt) 2017-09-26
EP3690049A1 (en) 2020-08-05
CA2921518A1 (en) 2014-11-06
ZA201507216B (en) 2017-08-30
US10927372B2 (en) 2021-02-23
AU2017200365B2 (en) 2018-11-08
MX373306B (es) 2020-05-20
BR112015027369A2 (pt) 2017-09-26
NZ728517A (en) 2021-12-24
CR20150612A (es) 2016-03-03
BR112015027319A8 (pt) 2018-01-02
AU2017200365A1 (en) 2017-02-23
PE20152002A1 (es) 2016-01-21
JP2018183184A (ja) 2018-11-22
CN108064162A (zh) 2018-05-22
HRP20190987T1 (hr) 2019-09-20
JP6866459B2 (ja) 2021-04-28
EA036584B1 (ru) 2020-11-26
MX2019010441A (es) 2019-10-17
WO2014179625A1 (en) 2014-11-06
CN110079524A (zh) 2019-08-02
AU2019204784A1 (en) 2019-07-25
KR20160003723A (ko) 2016-01-11
AU2018267625B2 (en) 2020-09-10
BR122018009831B1 (pt) 2021-12-21
JP6639629B2 (ja) 2020-02-05
RU2015151200A (ru) 2019-01-14
HK1221404A1 (en) 2017-06-02
AU2022202770A1 (en) 2022-05-19
UA120287C2 (uk) 2019-11-11
US10883104B2 (en) 2021-01-05
EP4529927A3 (en) 2025-06-18
IL261901A (en) 2018-10-31
US9181549B2 (en) 2015-11-10
AU2017200950B2 (en) 2019-01-17
EA031393B1 (ru) 2018-12-28
WO2014179627A9 (en) 2015-02-26
NL301341I2 (nl) 2025-10-02
AU2014259755A1 (en) 2015-10-22
RU2686080C2 (ru) 2019-04-24
JP6216444B2 (ja) 2017-10-18
AU2017200365C1 (en) 2019-04-18
PT3524680T (pt) 2021-01-04
KR20220108195A (ko) 2022-08-02
IL296543A (en) 2022-11-01
AU2014259759A1 (en) 2015-10-22
KR20180051678A (ko) 2018-05-16
ME03390B (me) 2020-01-20
MY178929A (en) 2020-10-23
RU2019124314A (ru) 2019-08-21
CN105378085A (zh) 2016-03-02
JP7429103B2 (ja) 2024-02-07
KR20190084138A (ko) 2019-07-15
KR20160002976A (ko) 2016-01-08
MX373334B (es) 2020-05-04
US20180002693A1 (en) 2018-01-04
US20140343123A1 (en) 2014-11-20
US20150126720A1 (en) 2015-05-07
IL273312A (en) 2020-04-30
EP2992009A1 (en) 2016-03-09
AU2019203674A1 (en) 2019-06-27
KR20230113835A (ko) 2023-08-01
KR20160002975A (ko) 2016-01-08
EA201592093A1 (ru) 2016-06-30
AU2014259756A1 (en) 2015-10-22
MX384824B (es) 2025-04-01
CN105378085B (zh) 2019-02-15
RU2015151204A3 (enExample) 2018-03-27
US20190055554A1 (en) 2019-02-21
EP2992098B1 (en) 2019-03-27
MX2021008901A (es) 2021-08-19
IL284593B (en) 2022-10-01
IL315582A (en) 2024-11-01
DK2991656T3 (da) 2020-03-23
EP2991656A4 (en) 2017-02-22
JP2021074021A (ja) 2021-05-20
CN112921036B (zh) 2025-08-19
MX2015015264A (es) 2016-08-12
WO2014179629A3 (en) 2015-01-22
RU2018136140A (ru) 2018-12-17
US11299736B1 (en) 2022-04-12
CA2921167C (en) 2025-05-20
RS58981B1 (sr) 2019-08-30
BR112015027377B1 (pt) 2023-01-10
AU2024200296A1 (en) 2024-02-08
JP2023113843A (ja) 2023-08-16
KR102315836B1 (ko) 2021-10-22
JP6652602B2 (ja) 2020-02-26
AU2017203436A1 (en) 2017-06-08
IL296543B2 (en) 2025-02-01
KR102712053B1 (ko) 2024-10-02
AU2017200950A1 (en) 2017-03-02
AU2018267625A1 (en) 2018-12-13
ES2778442T3 (es) 2020-08-10
IL270464B (en) 2021-07-29
NZ725538A (en) 2021-02-26
CY1123369T1 (el) 2021-12-31
JP6387084B2 (ja) 2018-09-05
NO2025037I1 (no) 2025-08-13
KR102212275B1 (ko) 2021-02-05
US20160017323A1 (en) 2016-01-21
CN119913147A (zh) 2025-05-02
PH12018501963A1 (en) 2020-07-20
IL273184A (en) 2020-04-30
CN105392488A (zh) 2016-03-09
AU2019200820B2 (en) 2020-04-30
JP2016526874A (ja) 2016-09-08
RU2015151202A3 (enExample) 2018-03-27
LT2992098T (lt) 2019-07-10
US20160076032A1 (en) 2016-03-17
CL2015003217A1 (es) 2016-07-08
CN108064162B (zh) 2021-12-03
AU2014259750A1 (en) 2015-10-22
DOP2016000287A (es) 2017-02-15
IL263843B (en) 2020-03-31
EP2992097A2 (en) 2016-03-09
EP3633039A1 (en) 2020-04-08
AU2014259756B2 (en) 2017-02-23
DK2992098T3 (da) 2019-06-17
PL2992009T3 (pl) 2020-11-30
RU2018112167A (ru) 2019-03-07
BR112015027322A2 (pt) 2017-09-26
IL283660A (en) 2021-07-29
CN105378082A (zh) 2016-03-02
CN113293163A (zh) 2021-08-24
AU2022202770B2 (en) 2024-10-03
CA2921167A1 (en) 2014-11-06
KR20210014758A (ko) 2021-02-09
BR112015027377A2 (pt) 2017-08-29
ES2730015T3 (es) 2019-11-07
US20240352455A1 (en) 2024-10-24
KR20230006933A (ko) 2023-01-11
AU2014259759B2 (en) 2020-06-18
CR20190269A (es) 2019-09-13
DOP2015000268A (es) 2015-11-30
AU2019204784C1 (en) 2022-11-03
WO2014179626A2 (en) 2014-11-06
EP2991661B1 (en) 2019-03-13
KR20210129257A (ko) 2021-10-27
JP2024010070A (ja) 2024-01-23
HUE043697T2 (hu) 2019-09-30
RU2650510C2 (ru) 2018-04-16
US20230151365A1 (en) 2023-05-18
PH12015502493A1 (en) 2016-02-22
KR102235678B1 (ko) 2021-04-05
RU2018136140A3 (enExample) 2022-04-27
CA2921162A1 (en) 2014-11-06
IL242124B (en) 2019-02-28
CN105377887A (zh) 2016-03-02
RU2015151199A3 (enExample) 2018-03-27
JP2020074787A (ja) 2020-05-21
IL242132B (en) 2018-10-31
JP2025174962A (ja) 2025-11-28
JP6995478B2 (ja) 2022-01-14
IL274064B (en) 2021-06-30
IL264580B (en) 2020-04-30
IL284593B2 (en) 2023-02-01
AU2019204784B2 (en) 2022-01-27
RS60796B1 (sr) 2020-10-30
IL264241A (en) 2019-02-28
RU2697152C2 (ru) 2019-08-12
AU2014259757B2 (en) 2017-03-02
CN112921036A (zh) 2021-06-08
MA60161B1 (fr) 2025-02-28
KR20160002977A (ko) 2016-01-08
KR102482890B1 (ko) 2022-12-30
IL273205A (en) 2020-04-30
IL284593A (en) 2021-08-31
KR102651423B1 (ko) 2024-03-27
US20150176007A1 (en) 2015-06-25
EP2991656B1 (en) 2019-12-18
DOP2021000095A (es) 2021-09-15
JP2020039354A (ja) 2020-03-19
MX2015015234A (es) 2016-10-03
AU2014259750B2 (en) 2019-02-28
SMT201900316T1 (it) 2019-07-11
AU2020233603A1 (en) 2020-10-01
KR20210037752A (ko) 2021-04-06
US9181550B2 (en) 2015-11-10
CA2921509A1 (en) 2014-11-06
AU2019203674B2 (en) 2021-03-25
US20210087566A1 (en) 2021-03-25
US12291709B2 (en) 2025-05-06
US10683499B2 (en) 2020-06-16
JP2021107408A (ja) 2021-07-29
RU2670614C2 (ru) 2018-10-24
JP2016526018A (ja) 2016-09-01
JP2018027091A (ja) 2018-02-22
EP2992098A2 (en) 2016-03-09
EP4438129A3 (en) 2025-01-15
US20160090595A1 (en) 2016-03-31
JP7177127B2 (ja) 2022-11-22
SI2992098T1 (sl) 2019-06-28
ZA201507218B (en) 2023-09-27
KR101857707B1 (ko) 2018-05-14
NZ712737A (en) 2021-08-27
PT2992009T (pt) 2020-09-21
NZ631552A (en) 2017-02-24
WO2014179620A1 (en) 2014-11-06
PT2992098T (pt) 2019-07-05
CN110042098A (zh) 2019-07-23
IL263843A (en) 2019-01-31
HK1221486A1 (en) 2017-06-02
JP2020058370A (ja) 2020-04-16
FR25C1033I1 (fr) 2025-11-21
MX2020004209A (es) 2020-08-13
RU2015151200A3 (enExample) 2019-01-14
PE20161430A1 (es) 2017-01-06
US20200224198A1 (en) 2020-07-16
MX2020002184A (es) 2020-07-14
RU2670614C9 (ru) 2018-11-23
SG10201801813YA (en) 2018-04-27
AU2014259757A1 (en) 2015-10-22
CN105378082B (zh) 2020-06-09
SG11201508870VA (en) 2015-11-27
US20250346899A1 (en) 2025-11-13
US11851655B2 (en) 2023-12-26
US9714421B2 (en) 2017-07-25
SG10201801507RA (en) 2018-03-28
HK1221475A1 (en) 2017-06-02
US9145558B2 (en) 2015-09-29
SG11201508800WA (en) 2015-11-27
US9127276B2 (en) 2015-09-08
RU2019110030A (ru) 2019-05-06
IL264241B (en) 2020-04-30
IL272617A (en) 2020-03-31
EP2991656A2 (en) 2016-03-09
AU2019200820A1 (en) 2019-02-28
US20180273952A1 (en) 2018-09-27
JP6592486B2 (ja) 2019-10-16
EP4529927A2 (en) 2025-04-02
AU2021204244B2 (en) 2023-10-19
EP4155403A1 (en) 2023-03-29
RU2015151202A (ru) 2017-06-06
EP2992097A4 (en) 2017-01-04
AU2021204244A1 (en) 2021-07-22
PL2992098T3 (pl) 2019-09-30
HK1221485A1 (en) 2017-06-02
JP2020007361A (ja) 2020-01-16
LT2992009T (lt) 2020-11-10
US20210024923A1 (en) 2021-01-28
MX2015015239A (es) 2016-10-03
ES2885174T3 (es) 2021-12-13
ES2819213T3 (es) 2021-04-15
JP2024116224A (ja) 2024-08-27
CN105392488B (zh) 2021-04-30
AU2020207820A1 (en) 2020-08-06
RU2699985C2 (ru) 2019-09-11
US20240401038A1 (en) 2024-12-05
BR112015027377A8 (pt) 2017-10-03
EP2992097B1 (en) 2019-11-06
US20180273953A1 (en) 2018-09-27
CN110042098B (zh) 2023-02-24
EP2991661A1 (en) 2016-03-09
AU2014259755B2 (en) 2018-08-30
US20180044676A1 (en) 2018-02-15
US20160090596A1 (en) 2016-03-31
HUE050394T2 (hu) 2020-11-30
BR112015027369A8 (pt) 2018-01-02
HK1221403A1 (en) 2017-06-02
IL242125B (en) 2019-02-28
NZ631512A (en) 2016-10-28
US20160076030A1 (en) 2016-03-17
US20210130823A1 (en) 2021-05-06
JP2025072530A (ja) 2025-05-09
BR112015027321A8 (pt) 2018-01-02
BR112015027322A8 (pt) 2018-01-02
KR102424855B1 (ko) 2022-07-26
WO2014179626A3 (en) 2015-02-26
JP7633311B2 (ja) 2025-02-19
PH12015502493B1 (en) 2019-09-25
US20190367914A1 (en) 2019-12-05
JP2022017514A (ja) 2022-01-25
JP7339294B2 (ja) 2023-09-05
JP2016522683A (ja) 2016-08-04
JP2016523515A (ja) 2016-08-12
KR102558571B1 (ko) 2023-07-21
WO2014179629A2 (en) 2014-11-06
IL274064A (en) 2020-06-30
NZ753018A (en) 2022-01-28
US9957504B2 (en) 2018-05-01
US9163239B2 (en) 2015-10-20
CN110079524B (zh) 2024-09-24
US20210395734A1 (en) 2021-12-23
EP2992009B1 (en) 2020-06-24
JP6456362B2 (ja) 2019-01-23
HRP20201378T1 (hr) 2020-11-27
US9932581B2 (en) 2018-04-03

Similar Documents

Publication Publication Date Title
UA121017C2 (uk) Композиція і спосіб моделювання експресії hbv
JP6882411B2 (ja) 成長ホルモン受容体発現を調節するための組成物及び方法
AU2015252858C1 (en) Compositions and methods for modulating Complement Factor B expression
RU2782034C2 (ru) Композиции и способы модулирования экспрессии hbv и ttr
HK40053557A (en) Compositions and methods for modulating ttr expression
EA046363B1 (ru) Олигомерные соединения для модулирования экспрессии ttr
NZ764037A (en) Compositions and methods for modulating growth hormone receptor expression
NZ764037B2 (en) Compositions and methods for modulating growth hormone receptor expression
NZ728517B2 (en) Compositions and methods for modulating ttr expression